

Stephen J. Freedland, M.D.

Positions:

- 1997-2003 Urology Residency, UCLA School of Medicine
- 2000 – Principal Investigator, SEARCH Database
- 2003 – 2005 Urological Oncology Fellowship, Brady Urological Institute, The Johns Hopkins University School of Medicine
- 2005 – 2008 Assistant Professor, Division of Urologic Surgery, Department of Surgery, Duke University
- 2005 – 2008 Assistant Professor, Department of Pathology, Duke University
- 2005 – 2014 Member, Duke Clinical Research Institute
- 2005 – Staff Physician, Department of Surgery, Durham VA Medical Center
- 2006 – 2014 Member, CORE Research Leadership Team, Division of Urologic Surgery, Department of Surgery, Duke University
- 2006 – 2009 Director, Outcomes and Translational Research, Division of Urologic Surgery, Department of Surgery, Duke University
- 2007 – 2014 Associate Program Director, Urology Residency, Division of Urologic Surgery, Department of Surgery, Duke University
- 2008 – 2014 Member, Duke Comprehensive Cancer Center
- 2008 – 2009 Associate Professor, Division of Urologic Surgery, Department of Surgery, Duke University
- 2008 – 2009 Associate Professor, Department of Pathology, Duke University
- 2009 – 2014 Associate Professor with Tenure, Division of Urologic Surgery, Department of Surgery, Duke University
- 2009 – 2014 Associate Professor with Tenure, Department of Pathology, Duke University
- 2009 – 2012 Vice Chief of Research, Division of Urologic Surgery, Department of Surgery, Duke University
- 2010 – 2012 Associate Director for Clinical Research, Genitourinary Cancer Program, Duke Cancer Institute, Duke University
- 2012 – 2014 Residency Director, Urology Research Fellowship, Division of Urologic Surgery, Department of Surgery, Duke University
- 2013 – 2014 Director, Duke KURe Scholars Program
- 2015 – Professor of Surgery (Urology), Cedars Sinai Medical Center
- 2015 – Director, Center for Integrated Research on Cancer and Lifestyle, Cedars Sinai Medical Center
- 2015 – Co-Director, Cancer Prevention and Genetics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center
- 2015 – Associate Director, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center

Education:

- 1993 BS Biology, Summa Cum Laude, UCLA
Concentration in Molecular, Cellular, and Developmental Biology
- 1995 Passed Part I USMLE
- 1997 Passed Part II USMLE
- 1997 MD from University of California at Davis, School of Medicine
- 1998 Passed Part III USMLE
- 2003 Passed Qualifying (Part 1) Examination of the American Board of Urology

- 2008 Passed Qualifying (Part 2) Examination of the American Board of Urology
- 2008 Board Certification in Urology

Honors and Awards:

- 1989 Eagle Scout, Boy Scouts of America
- 1992 Golden Key National Honor Society, UCLA
- 1993 Phi Beta Kappa, UCLA
- 1993 Community Service Award for outstanding contributions to the UCLA community, UCLA
- 1993 Honors in Biology, UCLA
- 1995 Medical Student Award for Excellence, American Federation for Clinical Research
- 1995 Award for Academic Excellence and Achievement, American Society of Clinical Pathologists
- 1995-6 Honorary Membership, American Federation for Clinical Research
- 1997 Robert E. Stowell Award for Excellence in Pathology, UC Davis School of Medicine
- 1997 Award for Excellence in Urology, UC Davis School of Medicine
- 2003- Who's Who in Science and Engineering, 7th edition
- 2003- Who's Who in Medicine and Healthcare, 4th edition
- 2006- Who's Who of Emerging Leaders, 1st edition
- 2008- Who's Who of Medicine Higher Education
- 2009 Tenure, Duke University
- 2010 Reviewer of the Month, June 2010, European Urology
- 2010 Reviewer's Roll of Honour, BJU International
- 2011 Marquis Who's Who in America
- 2011 Reviewer's Roll of Honour, BJU International

Research Awards and Fellowships:

- 1994-7 Predoctoral Research Fellowship, UC Davis School of Medicine
- 1995 E.E. Osgood Award for Excellence in Research, Western Student Medical Research Forum
- 1995 Morton Levitt Research Fellowship, UC Davis School of Medicine
- 1996 Alpha Omega Alpha Research Grant
- 1997 Morton Levitt Research Award, UC Davis School of Medicine
- 1997 Loren D. Carlson Student Research Award, UC Davis School of Medicine
- 2000 Abe Zarem Research Award, UCLA Department of Urology
- 2001 1st Prize, Miley B. Wesson Resident Essay Competition, AUA Western Section
- 2001 2nd Prize Miley B. Wesson Resident Essay Competition, AUA Western Section
- 2002 2nd Prize, AUA/ACMI Prize Essay Contest, Laboratory Research Category, National AUA
- 2002 3rd Prize, Miley B. Wesson Resident Essay Competition, AUA Western Section
- 2003 1st Prize, Miley B. Wesson Resident Essay Competition, AUA Western Section
- 2003 Outstanding Poster Presentation, Society of Urological Oncology Winter Meeting
- 2003-5 Department of Defense, Health Disparity Training-Prostate Scholar Award
- 2004-5 AFUD/AUAER Research Scholar
- 2005 2nd Prize, AUA/ACMI Prize Essay Contest, Clinical Research Category, National AUA

- 2005 3rd Prize, AUA/ACMI Prize Essay Contest, Clinical Research Category, National AUA
- 2005 Alfred Blalock Research Award, Johns Hopkins Young Investigator's Day
- 2005 Foundation Merit Award, ASCO
- 2006 3rd Prize, AUA/ACMI Prize Essay Contest, Clinical Research Category, National AUA
- 2006 3rd Prize, AUA/ACMI Prize Essay Contest, Laboratory Research Category, National AUA
- 2006 AUA Foundation/Astellas Rising Star in Urology Award
- 2007 2nd Prize, AUA/ACMI Prize Essay Contest, Laboratory Research Category, National AUA
- 2007 1st Prize, AUA/ACMI Prize Essay Contest, Clinical Research Category, National AUA (senior author)
- 2007 Young Investigator Award, Society of Basic Urological Research
- 2009 1st Prize, AUA/ACMI Prize Essay Contest, Laboratory Research Category, National AUA
- 2010 3rd Prize, AUA/ACMI Prize Essay Contest, Laboratory Research Category, National AUA (senior author)
- 2012 3rd Prize, AUA/ACMI Prize Essay Contest, Clinical Research Category, National AUA (senior author)
- 2012 1st Prize, Ambrose Reed Socioeconomic Prize Essay Contest, National AUA (senior author)

Research Grants Received:

- 2003-5: PI: 100% effort, DOD grant #PC030666 - "Molecular Profiling of Prostate Cancer Precursor Lesions (PIN and PIA) in African-American and Caucasian Men"
- 2005-6: PI: 10% effort, Prostate Cancer Foundation – "Role of a Ketogenic Diet in Prostate Cancer Growth and Progression"
- 2005-7: PI: 15% effort, DOD grant # PC050785 - "Ketogenesis, Ketogenic diet, and Prostate Cancer Progression"
- 2005-10: PI: 40% effort, DOD grant # PC051369, "Molecular Dissection of the Association between Obesity and Aggressive Prostate Cancer"
- 2006-7: PI: 5% effort, Atkins Foundation, "Preclinical Validation Trial of Low-Carbohydrate Ketogenic Diet on Prostate Cancer Growth and Progression"
- 2007-8: Co-PI: 1% effort, Atkins Foundation, "Carbohydrate Restriction plus Radiation to Delay Prostate Cancer Growth in a Xenograft Model"
- 2007-8: PI: 10% effort, Prostate Cancer Foundation – "Weight loss and gain and cancer free survival after radical prostatectomy in a multiethnic cohort"
- 2007-9: Mentor (Hamilton, PI): 2% effort, DOD, "Racial Differences in the Association between Statin use and Prostate Cancer Progression after Radical Prostatectomy"
- 2007-10: Co-Investigator (Moul, PI): 2% effort, DOD, "NCCU/BBRI-Duke/Urology Partnership in Prostate Cancer Research"
- 2008-11: Co-PI: 10% effort, Prostate Cancer Foundation – "Prevention of Treatment and Disease-Related Morbidity During Androgen Deprivation Therapy: A Multicenter Proposal"
- 2008-11: PI: 10% effort, Atkins Foundation, "Randomized Controlled Clinical Trial of Carbohydrate Restriction among men Initiating Androgen Deprivation Therapy for Prostate Cancer"
- 2008-13: Co-PI: 25% effort, NIH 5R01 CA131235-03, "Resveratrol, Carbohydrate Restriction and Prostate Cancer Progression"

2009-11: Mentor (Keto, PI): 1% effort, DOD, “Racial Disparities in Metformin Use and Potential Prostate Cancer Therapy”

2009-11: Co-investigator (Bañez, PI): 2% effort, DOD, “Racial Differences in Obesity-Related Hemodilution of Prostate Cancer Serum Markers”

2009-12: Co-investigator (Richardson, PI): 6% effort, NIH P20 MD000175-09, “EXPORT-NCMHD Research Center of Excellence at NCCU”

2009-13: Mentor (Muller, PI): 1% effort, DOD, “Recurrence after Radical Prostatectomy: Is it Different in Black Men?”

2009-13: Co-investigator (Walters, PI): 5% effort, NIH R01, “Prostate Specific Antigen Practices and Outcomes in the Elderly”

2010-13: Co-investigator (Richardson, PI): 5% effort, NIH 1U54 CA156735-01, “NCCU-LCCC Partnership in Cancer Research”

2011-13: Co-investigator (Shinohara, PI): 5% effort, DOD, PC100266 “Targeting a Novel Intracellular Isoform of Osteopontin in Innate Immunity to Suppress Prostate Cancer Progression”

2011-16: Co-investigator (Ostrer, PI): 10% effort, NIH, 1 U01 CA-158431-01 “Genomics and Predictive Modeling of Prostate Cancer Health Disparity”

2012-14: Mentor (Masko, PI): 0% effort, DOD, “Do Racial Differences in Branched Amino Acid Metabolism and Genetics Contribute to Prostate Cancer Racial Disparity”

2012-17: PI: 50% effort, NIH 1K24CA160653-01A1, “Midcareer Investigator Award”

2012: PI: 10% effort, AUA Foundation, “AUA Foundation Success Award – Supplement to NIH Midcareer Investigator Award”

2012-4: PI: 1% effort, Atkins Foundation, “Randomized Controlled Clinical Trial of Carbohydrate Restriction among men with a Rising PSA after Failed Primary Therapy for Prostate Cancer”

2012-15: Co-investigator (Ostrer, PI): 10% effort, DOD, PC110974, “Genomic Basis of Prostate Cancer Health Disparity among African-American Men”

2012-14: Co-investigator (Bachelder, PI): 10% effort, DOD, “Targeting Prostate Cancer Stem-like Cells Through Cell Surface-expressed GRP78”

2013-14: PI: 5% effort, NIH 1 K12 DK100024-01, “Duke KURe Program”

2014-19: Co-investigator (Vickers, PI): 4% effort, NIH R01 CA179115, “Dynamic, Multi-Cohort Prediction Modeling of Prostate Biopsy Outcome”

2015-17: Co-investigator (Fowke, PI): 10% effort, DOD PC141010, “Magnesium Predicts High-Grade Prostate Cancer and a Poorer Prognosis among Black and White Men”

2015-18: PI: 10% effort, DOD, “Disparities in Intratumoral Steroidogenesis”

2015-19: PI: 20% effort, CDC 1U01DP006079-01, “The Epidemiology of Interstitial Cystitis in a Nationwide Multiethnic VA Cohort”

Reviewer for Peer Reviewed Journals

2002 – current Urology

2002 – current Journal of Urology

2004 – current Prostate

2004 – current Ethnicity & Disease

2004 – current Asian Journal of Andrology

2004 – current Cancer Causes and Control

2004 – current Clinical Cancer Research

2004 – current International Journal of Cancer

2005 – current BMC Cancer

2005 – current	Cancer Detection and Prevention
2005 – current	Journal of Clinical Oncology
2005 – current	Cancer
2005 – current	Archives of Internal Medicine
2005 – current	Cancer Epidemiology Biomarkers and Prevention
2005 – current	Prostate Cancer and Prostatic Disease
2006 – current	JAMA
2006 – current	European Urology
2006 – current	JNCI
2006 – current	Cancer Research
2006 – current	International Brazilian Journal of Urology
2006 – current	British Journal of Urology
2006 – current	European Journal of Surgical Oncology
2006 – current	Issues in Urology
2006 – current	Urological Oncology
2006 – current	Nature Clinical Practice Urology
2007 – current	Expert Review of Endocrinology and Metabolism
2007 – current	Molecular Carcinogenesis
2007 – current	Future Drugs
2007 – current	Future Oncology
2007 – current	American Journal of Epidemiology
2007 – current	American Journal of Pathology
2007 – current	Cancer Investigation
2008 – current	Lancet Oncology
2008 – current	British Journal of Cancer
2008 – current	Molecular Cancer Therapeutics
2008 – current	Cancer Prevention Research
2009 – current	Indian Journal of Cancer
2009 – current	Expert Review of Anticancer Therapy
2009 – current	European Journal of Applied Physiology
2009 – current	Cancer Biomarkers
2009 – current	International Journal of Developmental Neuroscience
2009 – current	Journal of Surgical Research
2009 – current	Yonsei Medical Journal
2009 – current	International Journal of Men's Health
2009 – current	European Journal of Cancer
2009 – current	International Urology and Nephrology
2010 – current	Obesity
2010 – current	Aging Male
2010 – current	Obesity Reviews
2011 – current	New England Journal of Medicine
2011 – current	PLoS ONE
2012 – current	Endocrine Related Cancers
2012 – current	Prostate Cancer
2012 – current	Diabetes/Metabolism Research and Reviews
2012 – current	Cancer Letters
2012 – current	Nature Reviews Cancer
2013 – current	Lancet Diabetes & Endocrinology
2016 – current	Hormones and Cancer

Abstract reviewer for meetings

2007 – current AUA Annual Meeting
2008 – current EAU Annual Meeting
2009 – 2015 Southeastern section of the AUA Annual Meeting

American Urological Association Invited Events

2007-12 Abstract reviewer, prostate cancer basic science
2007 Co-Director, IC course: Evidence based medicine
2007 Invited speaker, Basic Science Forum
2007 Invited speaker, Plenary
2007-8 Poster session moderator, AUA National Meeting
2008-12 Abstract team leader, prostate cancer basic science
2008 Invited speaker, Endocrine Forum
2008 Press briefing session moderator, AUA National Meeting
2008-10 Co-Director, IC course: Statistics for the non-statistician
2009 Attendee, AUA Research Council Meeting
2009 Podium moderator, AUA National Meeting
2009 Participant, National Urology Research Agenda
2010 AUA-EAU Exchange Fellowship
2010-12 Poster session moderator, AUA National Meeting
2011 Invited speaker, Plenary
2012 Co-Director, IC course: Androgen deprivation therapy and the treatment of advanced prostate cancer
2015 Abstract reviewed, advanced prostate cancer

National Committee work

2009 Participant, National Urology Research Agenda
2011 – Member, AUA Guideline panel on prostate cancer screening
2011 – Member, AUA Guideline panel on castrate resistant prostate cancer
2014 – Member, AUA Guideline panel on clinically localized prostate cancer
2014-15 Co-Chair, ASCO Guideline panel on adjuvant and salvage radiotherapy after prostatectomy
2014 – Member, AUA Early Career Investigator Workshop Organizing Committee

Institutional Committee work

2006 – 2014 Member, CORE Research Leadership Team, Division of Urology, Department of Surgery, Duke University
2008 – 2015 Member, Durham VA IRB
2010 – 2014 Member, Clinical Sciences Faculty Council, Duke University
2015 – Member, Protocol Review and Monitoring Committee, Cedars-Sinai Medical Center
2015 – Member, Investigator Initiated Trial Working Group, Cedars-Sinai Medical Center
2015 – Member, Cancer Grants Workshop
2015 – Member, Samuel Oschin Comprehensive Cancer Institute Executive Committee, Cedars-Sinai Medical Center

Journal Editorial Positions

2007 – 2010	Editorial board, Prostate Cancer and Prostatic Disease
2007 – current	Editorial board, European Urology
2009 – current	Editorial board, International Journal of Urology
2010 – current	Editorial board, BJUI
2010 – current	Editor-in-Chief, Prostate Cancer and Prostatic Disease
2011 – 2014	North American Editor, European Urology
2014 – current	Advisory Board, Nature Reviews Urology
2015 – current	Consulting editor, European urology
2015 –	Editorial Board, Cancer Prevention Research
2015 –	Editorial Board, Asian Journal of Andrology

Grants reviewed

2007	Ad-hoc reviewer, Department of Defense Prostate Cancer Grants
2008	Ad-hoc reviewer, CALGB
2008	Ad-hoc reviewer, Prostate Cancer Foundation, Australia
2008	Ad-hoc reviewer, Genesis Oncology Trust, New Zealand
2009	Ad-hoc reviewer, Italian Ministry of Health, Italy
2010	Ad-hoc reviewer, National Medical Research Council, Singapore
2013	Ad-hoc reviewer, NCI/NIH SPORE Program
2013	Ad-hoc reviewer, NCI/NIH SBIR Program
2013	Ad-hoc reviewer, Canadian Cancer Society, Career Development awards in cancer prevention
2014	Ad-hoc reviewer, NCI/NIH P01 Program
2015	Ad-hoc reviewer, NCI/NIH P01 Program
2015	Ad-hoc reviewer, NCI/NIH SCORE Program

Extracurricular Activities:

1989	UCLA Marching Band, trumpet
1990	UCLA Varsity Band, trumpet
1990-7	Assistant Scout Master, Boy Scouts of America
1992-3	Social Chair, UCLA Chapter of Golden Key National Honor Society
1994-7	Co-President, Jewish Medical Students Association
1994-5	UC Davis School of Medicine representative to the Western Student Medical Research Committee
1995-6	Vice Chairman, Western Student Medical Research Committee
1996-7	Chairman, Western Student Medical Research Committee
1997-8	Senior Advisor, Western Student Medical Research Committee

Interests

Spending time with my fiancé and children (13-year old daughter, 9-year old son), reading (especially business/leadership books), international travel, and sports, particularly basketball.

Research Papers

1. **Freedland SJ**, Malone RW, Borchers HM, Zadourian Z, Malone J, Bennett MJ, Nantz M, Li JH, Gumerlock PH, and Erickson KL. Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity. *Biochem Mol Med* 1996;59: 144-153

2. Bringaud F, Striebeck R, Frech GC, **Freedland SJ**, Turck C, Byrne EM, and Simpson L. Mitochondrial glutamate dehydrogenase from *Leishmania tarentolae* is a guide RNA-binding protein. *Mol Cell Bio* 1997;17: 3915-3923
3. Kisich KO, **Freedland SJ**, and Erickson KL. Factors altering ribozyme-mediated cleavage of tumor necrosis factor- α mRNA *in vitro*. *Biochem Biophys Res Com* 1997;236: 205-211
4. **Freedland SJ**, Cha I, and Turek PJ. Non-palpable leydig cell tumors diagnosed by fine needle aspiration. *J Urol* 1997;158: 543-544
5. **Freedland SJ** and Shoskes DA. Economic impact of delayed graft function and suboptimal kidneys. *Trans Rev* 1999;13: 23-30
6. Aronson WJ and **Freedland SJ**. Can we lower the mortality rate of black men with prostate cancer? *J Urol* 2000;163: 150-151
7. **Freedland SJ**, Sutter ME, Naitoh J, Dorey F, Csathy GS, and Aronson WJ. Clinical characteristics in black and white men with prostate cancer in an equal access medical center. *Urol* 2000;55: 387-390
8. **Freedland SJ**, Jalkut M, Dorey F, and Aronson WJ. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. *Urol* 2000;56: 87-91
9. **Freedland SJ**, Dorey F, and Aronson WJ. Multivariate analysis of race and adverse pathological findings after radical prostatectomy. *Urol* 2000;56: 807-811
10. **Freedland SJ**, Dorey F, and Aronson WJ. Preoperative PSA velocity or doubling time does not predict adverse pathological features or biochemical recurrence following radical prostatectomy. *Urol* 2001;57: 476-480
11. **Freedland SJ**, Pantuck AJ, Zisman A, and Beldegrun AS. Tumor vaccines for metastatic renal cell carcinoma. *Rev in Urol* 2001;3: 21
12. **Freedland SJ**, Chao D, Pantuck AJ, Zisman A, and Beldegrun AS. New diagnostic and therapeutic modalities for RCC, TCC, and testicular cancer. *Rev in Urol* 2001;3: 33-35
13. **Freedland SJ**, Eilber KS, Palapattu GS, and Rajfer J. Conservative management of a grade IV renal laceration in a child. *Rev in Urol* 2001;3: 40-41
14. Chao D, **Freedland SJ**, Pantuck AJ, Zisman A, and Beldegrun AS. Bladder Cancer 2000: Molecular markers for the diagnosis of TCC. *Rev in Urol* 2001;3: 85-93
15. Chao D, Zisman A, **Freedland SJ**, Pantuck AJ, Said JW, and Beldegrun AS. Sarcomatoid renal cell carcinoma: Basic biology, clinical behavior and response to therapy. *Urol Onc* 2001;6: 265-275

16. Eilber KS, **Freedland SJ**, and Rajfer J. Obstructive uropathy secondary to ureteroinguinal herniation. Rev in Urol 2001;3: 207-208
17. Wieder JA, **Freedland SJ**, Pantuck AJ, Zisman A, and Belldegrun AS. Update on gene and immune based therapy for urologic malignancy. Urol Onc 2001;6: 231-238
18. **Freedland SJ** and Belldegrun AS. Towards a kidney cancer crystal ball: Better prognostication of patients with renal cell carcinoma. J Urol 2001;166: 73-74
19. Eilber KS, **Freedland SJ**, and Rajfer J. Polyarteritis nodosa presenting as hematuria and a testicular mass. J Urol 2001;166: 624
20. Zisman A, Pantuck AJ, **Freedland SJ**, and Belldegrun AS. Urology in the desert 2000: Highlights from the 76th annual meeting of the Western Section of the American Urological Association. Rev in Urol 2001;3: 99-101
21. **Freedland SJ**, Chao D, Pantuck AJ, Zisman A, and Belldegrun AS. Determining the optimal treatment for advanced bladder cancer. Rev in Urol 2001;3: 159-162
22. **Freedland SJ**, Chao D, Pantuck AJ, Zisman A, and Belldegrun AS. Rethinking staging and treatment for renal cell cancer. Rev in Urol 2001;3: 162-163
23. **Freedland SJ**, Bui MHT, Chao D, Pantuck AJ, Zisman A, and Belldegrun AS. Biomarkers for early detection and optimized treatment for transitional cell carcinoma. Rev in Urol 2001;3: 210-212
24. Chao D, Zisman A, Pantuck AJ, Gitlitz B, **Freedland SJ**, Said JW, Figlin RA, and Belldegrun AS. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 2002;167: 71-74
25. **Freedland SJ**, Mishkin F, and Shoskes DA. Effective renal plasma flow as calculated from a single blood sample following a Technetium-99m mercaptoacetyltriglycine renal scan can predict delayed graft function in renal transplantation. Tech Urol 2001;7: 281-284
26. **Freedland SJ**, Csathy GS, Dorey F, and Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical than prostate specific antigen or Gleason score for predicting prostatectomy. J Urol 2002;167: 516-520
27. **Freedland SJ**, Blanco-Yarosh M, Sun JC, Hale SJ, Elashoff DA, Litwin MS, Smith RB, Rajfer J, and Gritsch HA. Ketorolac-based analgesia improves outcomes for living kidney donors. Transplantation 2002;73: 741-745
28. Chao D, Zisman A, Pantuck AJ, **Freedland SJ**, Said JW, and Belldegrun AS. Changing concepts in the management of renal oncocytoma. Urol 2002;59: 635-642

29. **Freedland SJ**, Blanco-Yarosh M, Sun JC, Hale SJ, Elashoff DA, Rajfer J, and Gritsch HA. Effect of ketorolac on renal function after donor nephrectomy. *Urol* 2002;59: 826-830
30. **Freedland SJ**, Wieder JA, Jack GS, Dorey F, deKernion JB, and Aronson WJ. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. *J Urol* 2002; 168: 110-115
31. **Freedland SJ**, Pantuck AJ, Wieder JA, Zisman A, and Beldegrun AS. Immunotherapy of prostate cancer. *Curr Rep Urol* 2001;2: 242-247
32. **Freedland SJ**, Csathy GS, Dorey F, and Aronson WJ. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy. *Urol* 2002;60: 84-88
33. **Freedland SJ**, Amling CL, Dorey F, Kane CJ, Presti JC Jr., Terris MK, and Aronson WJ. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. *Urol* 2002;60: 670-674
34. Wieder J, Hu J, Bui M, **Freedland S**, and Beldegrun A. Case scenario: 69 year-old male with left spermatic cord mass. *Rev in Urol* 2002;4: 153-156
35. Berger F, Lee YP, Loening A, Chatziioannou A, **Freedland SJ**, Leahy R, Lieberman JR, Beldegrun A, Sawyers CL, and Gambhir SS. Whole body skeletal imaging in mice utilizing microPET : optimization of reproducibility and applications in animal models of bone disease. *Eur J Nucl Med Mol Imaging* 2002;29: 1225-1236
36. **Freedland SJ**, Kane CJ, Presti JC Jr., Terris MK, Amling CL, Dorey F, and Aronson WJ. Comparison of pre-operative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: Results from the SEARCH database. *J Urol* 2003;169: 969-973
37. **Freedland SJ**, Sutter ME, Dorey F, and Aronson WJ. Defining the ideal cut-point for determining PSA recurrence following radical prostatectomy. *Urol* 2003;61: 365-369
38. **Freedland SJ**, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, and Aronson WJ. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. *J Urol* 2003;169: 1325-1330
39. **Freedland SJ**, Seligson DS, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, and Beldegrun AS. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. *Prostate* 2003;55: 71-81
40. **Freedland SJ**, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Dorey F, and Terris MK. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. *Urol* 2003;61: 736-741

41. **Freedland SJ**, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Terris MK. Comparison of percent of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence following radical prostatectomy: results from the SEARCH database. *Urol* 2003;61: 742-747
42. **Freedland SJ**, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, and Belldegrun AS. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system. *Prostate* 2003;55: 299-307
43. Perry KT, **Freedland SJ**, Hu J, Phelan M, Kristo B, Gritsch AH, Rajfer J, and Schulam PG. Quality of life, pain, and return to normal activities following laparoscopic donor nephrectomy vs. open mini-incision donor nephrectomy. *J Urol* 2003;169: 2018-2021
44. **Freedland SJ**, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, and Amling CL. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. *J Urol* 2003;169: 2129-2135
45. **Freedland SJ**, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent of prostate needle biopsy cores with cancer is a significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: Results from the SEARCH database. *J Urol* 2003;169: 2136 -2141
46. **Freedland SJ**, Aronson WJ, Presti JC Jr., Kane CJ, Terris MK, Elashoff D, and Amling CL. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. *J Urol* 2003;169: 2142-2146
47. **Freedland SJ**, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, and Aronson WJ. Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. *Urol* 2003;61: 1187-1192
48. Ngo TH, Barnard RJ, Cohen P, **Freedland SJ**, Tran C, deGregorio F, Elshimali YI, Heber D, and Aronson WJ. Effect of isocaloric low-fat diet on human LAPC-4 prostate xenografts in SCID mice and the IGF axis. *Clin Can Res* 2003;9: 2734-2743
49. **Freedland SJ**, Amling CL, Terris MK, Presti JC Jr, Aronson WJ, Elashoff D, and Kane CJ. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH Database. *Pros Can Pros Dis* 2003;6: 261-265
50. **Freedland SJ**, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percentage of prostate needle biopsy cores with carcinoma from the most involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the SEARCH database. *Cancer* 2003;98: 2344-2350
51. **Freedland SJ** and DeKernion JB. Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma. *Rev in Urol* 2003;5: 191-195

52. **Freedland SJ.** Speaking with the experts: Does obesity affect outcome in prostate cancer? *Amer J Urol Rev* 2004;2: 317
53. **Freedland SJ.** Commentary on, "Risk of prostate cancer with psa < 4.0 ng/ml". *Amer J Urol Rev* 2004;2: 548
54. **Freedland SJ.** In reply. *J Clin Onc* 2005;23: 2435
55. **Freedland SJ,** Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, and Terris MK. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer. *J Clin Onc* 2004;22: 446-453
56. Ngo TH, Barnard RJ, Anton T, Tran C, Elashoff D, Heber D, **Freedland SJ,** and Aronson WJ. Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. *Can Res* 2004; 15:64: 1252-1254
57. **Freedland SJ,** Presti JC Jr, Kane CJ, Aronson WJ, Terris MK, Dorey F, and Amling CL. Do younger men have better biochemical outcomes after radical prostatectomy? *Urol* 2004;63: 518-522
58. **Freedland SJ,** Aronson WJ, Presti JC Jr. , Amling CL, Terris MK, Trock B, and Kane CJ. Predictors of prostate specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. *Cancer* 2004;100: 1633-1638
59. **Freedland SJ,** Partin AW, Epstein JI, and Walsh PC. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. *Cancer* 2004;100: 1646-1649
60. **Freedland SJ,** Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Aronson WJ. Pre-operative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade, and serum prostate specific antigen. *J Urol* 2004;171: 2215-2220
61. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, deKernion JB, and **Freedland SJ.** Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. *J Urol* 2004;171: 2260-2264
62. **Freedland SJ,** Mangold LA, Epstein JI, and Partin AW. Biopsy indication - a predictor of pathologic stage among men with pre-operative serum PSA levels ≤ 4.0 ng/mL and T1c disease. *Urol* 2004;63: 887-891
63. **Freedland SJ,** Terris MK, Presti JC Jr. , Amling CL, Kane CJ, Trock B, and Aronson WJ. Obesity and biochemical outcome following radical prostatectomy for organ-confined disease with negative surgical margins. *J Urol* 2004;172: 520-524
64. **Freedland SJ** and Aronson WJ. Examining the relationship between obesity and prostate cancer. *Rev in Urol* 2004;6: 73-81

65. **Freedland SJ** and Partin AW. Obesity and prostate cancer detection and progression. Rev in Urol 2004;6: 214-216
66. **Freedland SJ** and Partin AW. Prostate cancer update 2004. Rev in Urol 2005;7: 41-45
67. **Freedland SJ** and Partin AW. Best of the 2004 AUA annual meeting: Increasing awareness of the obesity epidemic. Rev in Urol 2004;6: 143-44
68. **Freedland SJ**, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr. , Trock B, and Amling CL. Biochemical outcome after radical prostatectomy among men with normal pre-operative serum prostate specific antigen levels. Cancer 2004;101: 748-753
69. **Freedland SJ**. Prostate cancer - fourth international congress. IDrugs 2004;8: 717-720
70. **Freedland SJ** and Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 2005;62: 243-252
71. **Freedland SJ**, Sokoll LJ, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Epstein JI, and Partin AW. Serum leptin and pathological findings at the time of radical prostatectomy. J Urol 2005; 173: 773-776
72. **Freedland SJ** and Aronson WJ. Obesity and prostate cancer. Urol 2005;65: 433-439
73. **Freedland SJ**, Isaacs WB, Mangold L, Yiu SK, Grubb KA, Partin AW, Epstein JI, Walsh PC, and Platz EA. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Can Res 2005;11: 2883-2888
74. **Freedland SJ**, Haffner MC, Landis PK, Saigal CS, and Carter HB. Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. Urol 2005;65: 1131-1136
75. **Freedland SJ**, Terris MK, Platz EA, and Presti JC. Body mass index as a predictor of prostate cancer: development vs. detection on biopsy. Urol 2005;66: 108-113
76. **Freedland SJ**, Ward JF, and Moul JW. PSA recurrence of prostate cancer - update 2006. Issues Urol 2006;18: 109-118
77. George D, Speca JC, and **Freedland SJ**. Textbook review: Comprehensive Textbook of Genitourinary Oncology. New Eng J Med 2006;355: 743
78. Fitzsimons NJ and **Freedland SJ**. Clinical considerations for prostate cancer screening and treatment in obese men. Sem Prevent Med 2006;2: 145-147
79. Rogers CG and **Freedland SJ**. Viable options for managing elevated postprostatectomy PSA. Contemporary Urol 2006;18: 38-44

80. **Freedland SJ.** Editorial comment. *J Urol* 2007;177: 106
81. Roehrborn CG, Chancellor MB, Assimos DG, Nickel JC, Brawer MK, **Freedland SJ**, Partin AW, Meacham RB, Rajfer J, Shapiro E, Stein JP, Lam JS, Leppert JT, Belldegrun AS. Best of the 2005 AUA annual meeting. *Rev in Urol* 2005;7: 145
82. **Freedland SJ** and Partin AW. Prostate cancer update: 2004: highlights from the 4th international prostate cancer congress, Grand Bahama Island, Bahamas, July 15-18, 2004. *Rev Urol* 2005;7: 41-45
83. Haffner MC, Landis PK, Saigal CS, Carter HB, and **Freedland SJ.** Health related quality of life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 era: impact of neurovascular bundle preservation. *Urol* 2005;66: 371-376
84. **Freedland SJ**, Humphreys EB, Mangold LA, Eisenberger M, Walsh PC, and Partin AW. Risk of prostate cancer specific mortality following biochemical recurrence after radical prostatectomy. *JAMA* 2005;294: 433-439
85. **Freedland SJ**, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold L, Isaacs WB, and Partin AW. Obesity and risk of biochemical progression after radical prostatectomy in a tertiary care referral center. *J Urol* 2005;174: 919-922
86. **Freedland SJ**, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, and Partin AW. Association between serum adiponectin and pathological stage and grade in men undergoing radical prostatectomy. *J Urol* 2005;174: 1266-1270
87. **Freedland SJ**, Mangold LA, Walsh PC, and Partin AW. The PSA era is alive and well: prostate specific antigen and biochemical progression following radical prostatectomy. *J Urol* 2005;174: 1276-1281
88. **Freedland SJ.** Obesity and prostate cancer: A growing problem. *Clin Can Res* 2005;11: 6763-6766
89. **Freedland SJ**, Grubb KA, Yiu SK, Nielsen ME, Mangold L, Isaacs WB, Epstein JI, and Partin AW. Obesity and capsular incision at the time of open retropubic radical prostatectomy. *J Urol* 2005;174: 1798-1801
90. **Freedland SJ**, Isaacs WB, Platz E, Terris M, Aronson WJ, Amling CL, Presti JC Jr., and Kane CJ. Prostate size and risk of high-grade, advanced prostate cancer, and biochemical progression after radical prostatectomy. *J Clin Onc* 2005;23: 7546-7554
91. **Freedland SJ**, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr., and Terris MK. Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy. *Clin Can Res* 2005;11: 7735-7742
92. Fitzsimons NJ and **Freedland SJ.** Prostate cancer screening and treatment recommendations for obese men. *Virtual Mentor* 2006;8: 323-326

93. **Freedland SJ**, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, Kane CJ, and Terris MK. Obesity, serum PSA, and prostate size: implications for prostate cancer detection. *J Urol* 2006;175: 500-504
94. **Freedland SJ**, Giovannucci E, and Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? *Cancer Causes Control* 2006;17: 5-9
95. **Freedland SJ**. Can we identify men with aggressive prostate cancer prior to treatment? *Nature Clin Prac Urol* 2005;12: 584-585
96. **Freedland SJ** and Partin AW. Prostate specific antigen: Update 2006, *Urol* 2006;67: 458-460
97. **Freedland SJ**, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr., and Terris MK. Delay in receiving radical prostatectomy and risk of biochemical progression among men with low-risk prostate cancer. *J Urol* 2006;175: 1298-1302
98. **Freedland SJ**, Krupski TL, and Moul JW. Update on outcomes research databases in prostate cancer 2006. *Curr Opin Urol* 2006;16: 168-172
99. Nielsen ME, Han M, Mangold L, Humphreys E, Walsh PC, Partin AW, and **Freedland SJ**. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. *J Urol* 2006;176: 515-519
100. Makarov DV, Humpheys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, and **Freedland SJ**. Pathologic outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 ng/ml vs. 4.1 to 6.0 mg/ml. *J Urol* 2006;176: 554-558
101. Mavropoulos J, Isaacs WB, Pizzo S, and **Freedland SJ**. Is there a role for a low-carbohydrate ketogenic diet in the management of prostate cancer? *Urol* 2006;68: 15-18
102. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Leung P, Hong-Gonzalez J, **Freedland SJ**, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, and Aronson WJ. Effect of altering dietary omega-6: omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2 and prostaglandin e-2. *Clin Can Res* 2006;12: 4662-4670
103. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr., Mangold LA, Humphreys E, Epstein JI, Partin AW, and **Freedland SJ**. Clinical and pathological outcome after radical prostatectomy for prostate cancer with a preoperative Gleason sum 8 to 10. *Cancer* 2006;107: 1265-1272
104. Nielsen ME, Zderic S, **Freedland SJ**, and Jarow JP. Insight into the pathogenesis of varicoceles: Relationship of varicocele with body mass index. *Urol* 2006;68: 392-396

105. **Freedland SJ**, Humphreys EB, Mangold LA, Eisenberger M, and Partin AW. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. *J Urol* 2006;176: 1404-1408
106. **Freedland SJ** and Partin AW. Optimal surgical management of the obese man with prostate cancer: laparoscopic or perineal radical prostatectomy. *Rev in Urol* 2005;7: 46-47
107. **Freedland SJ** and Partin AW. Dawning of the age of chemotherapy for prostate cancer. *Rev in Urol* 2005;7: 110-112
108. **Freedland SJ** and Partin AW. Early hormonal therapy for prostate cancer: the good, the bad, and the ugly. *Rev in Urol* 2005;7: 187-189
109. **Freedland SJ** and Partin AW. Detecting prostate cancer using molecular markers: uPM3. *Rev in Urol* 2005;7: 236-238
110. Cooperberg MR, **Freedland SJ**, Pasta DJ, Elkin EP, Presti, JC, Jr., Amling CL, Terris MK, Aronson WA, Kane CJ, and Carroll PR. Multi-institutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence following radical prostatectomy. *Cancer* 2006;107: 2384-2391
111. Fitzsimons NJ, Presti JC Jr., Kane CJ, Terris MK, Aronson WJ, Amling CL, and **Freedland SJ**. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? *J Urol* 2006;176: 2453-2458
112. Kane CJ, Presti JC Jr., Amling CL, Aronson WJ, Terris MT, and **Freedland SJ**. Changing nature of high-risk patients undergoing radical prostatectomy. *J Urol* 2007;177: 113-117
113. Rodriguez C, **Freedland SJ**, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, and Calle EE. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Can Epi Bio Prev* 2007;16: 63-69
114. **Freedland SJ**, Partin AW, Humphreys EB, Mangold LA, and Walsh PC. Radical prostatectomy for clinical stage T3 disease. *Cancer* 2007;109: 1273-1278
115. **Freedland SJ**, Kane CJ, Amling CL, Aronson WJ, Terris MT, and Presti JC Jr. Upgrading and downgrading of prostate needle biopsies: risk factors and clinical implications. *Urol* 2007;69: 495-499
116. King CR, **Freedland SJ**, Terris MK, Aronson WJ, Kane CJ, Amling CL, and Presti JC, Jr. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from the SEARCH database. *Urol* 2007;69: 732-737
117. **Freedland SJ**, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, and Partin AW. Death in patients with recurrent prostate cancer after radical prostatectomy:

PSADT subgroups and their associated contributions to all-cause mortality. *J Clin Onc* 2007;25: 176-1771

118. **Freedland SJ** and Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. *Epi Reviews* 2007;29: 88-97

119. King CR, **Freedland SJ**, Terris MK, Kane CJ, Amling CL, Aronson WJ and Presti JC, Jr.. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report by the SEARCH database study group. *Urol* 2007;69: 921-926

120. Buschemeyer WC and **Freedland SJ**. Obesity and prostate cancer: epidemiology and clinical implications. *Eur Urol* 2007;52: 331-343

121. **Freedland SJ** and Moul JW. PSA recurrence after definitive therapy. *J Urol* 2007;177: 1985-1991

122. Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ, T Aronson WJ, Presti JC Jr., Mangold LA, and **Freedland SJ**. Do racial differences in prostate size explain higher serum PSA concentrations among black men? *Urol* 2007;69: 1138-1142

123. Sajadi KP, Terris MK, Hamilton RJ, Cullen J, Amling CL, Kane CJ, Presti JC Jr, Aronson WJ, **Freedland SJ**. Prostate volume assessment by transrectal ultrasound depends on gland size and is not significantly affected by body mass index. *J Urol* 2007;178: 990-99

124. Hoyo C, Grubber J, Demark-Wahnefried W, Marks JR, **Freedland SJ**, Jeffreys AS, Grambow SC, Wenham RM, Walther PJ, and Schildkraut JM. Grade-specific prostate cancer association of IGF1 (CA) 19 repeats and IGFBP3-202A/C in blacks and whites. *J Natl Med Assoc* 2007;99: 718-722

125. Scales CD Jr., Presti JC Jr., Kane CJ, Terris MK, Aronson WJ, Amling CL, and **Freedland SJ**. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy – results from the SEARCH Database. *J Urol* 2007; 178: 1249-1252

126. Kang DE, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, and **Freedland SJ**. Risk stratification of men with Gleason 7-10 tumors by primary and secondary Gleason score: results from the SEARCH database. *Urol* 2007;70: 277-282

127. **Freedland SJ**. Obesity and prostate cancer: importance of race and stage of disease. *J Urol* 2007;178: 1842-1843

128. **Freedland SJ**, Hotaling JM, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, and Amling CL. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes – results from the SEARCH Database. *Eur Urol* 2008;53: 758-766

129. Hamilton RJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Race, biochemical recurrence, and PSADT after radical prostatectomy: results from the SEARCH database. *Cancer* 2007;110: 2202-2209
130. Hamilton RJ and **Freedland SJ**. Combining prostate cancer clinical features more accurately predicts final pathologic stage than any single variable alone. *Eur Urol*, 52: 1380, 2007.
131. Buschemeyer WC III, Hamilton RJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Is a positive bladder neck margin truly a T4 lesion in the PSA era? results from the SEARCH database. *J Urol* 2008;179: 124-9
132. **Freedland SJ**, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, and Isaacs WB. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. *Prostate* 2008;68: 11-19
133. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, and **Freedland SJ**. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. *JAMA* 2007;298: 2275-2280
134. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr., Amling CL, and **Freedland SJ**. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. *J Urol*, 2008;179: 523-527
135. Moul JW, Bañez LL, and **Freedland SJ**. Rising PSA in Non-metastatic prostate cancer. *Oncology* 2007;21: 1436-1445
136. Fitzsimons NJ, Sun LL, Dahm P, Moul JW, Madden J, Gan TJ, and **Freedland SJ**. A single-institution comparison between radical perineal and radical retropubic prostatectomy on peri-operative and pathological outcomes for obese men: an analysis of the duke prostate center database. *Urol* 2007;70: 1146-1151
137. Jayachandran J, **Freedland SJ**, and Moul JW. Long term effects of the treatment of testicular cancer. *CML-Urol*, 2008;14: 1-8
138. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki B, Thompson I, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, and **Freedland SJ**. Are the Partin tables accurate for African-American men in the United States? *Urol* 2008;71: 151-155
139. Price MM, Hamilton RJ, Robertson CN, Butts MC, and **Freedland SJ**. Body mass index, PSA, and digital rectal examination findings among participants in a prostate cancer screening clinic. *Urol* 2008;71: 787-791
140. Jayachandran J, Bañez LL, Levy D, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, and **Freedland SJ**. Risk stratification for biochemical recurrence among men with

positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. *J Urol* 2008;179: 1791-1796

141. Hamilton RJ, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and **Freedland SJ**. Limitations of PSADT following biochemical recurrence after radical prostatectomy: results from the SEARCH database. *J Urol* 2008;179: 1785-1789

142. Hamilton RJ and **Freedland SJ**. Review of recent evidence in support of a role for statins in the prevention of prostate cancer. *Curr Opin Urol* 2008;18: 333-339

143. Schroeck FR, Sun L, **Freedland SJ**, Albala DM, Mouraviev V, Polascik TJ, and Moul JW. Comparison of PSA recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic prostatectomy or robot-assisted laparoscopic radical prostatectomy. *BJU Intl*, 2008;102: 28-32

144. Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, **Freedland SJ**, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan M, and Sartor O. Prostate-specific antigen working group's guidelines on PSA doubling time. *J Urol* 2008;179: 2181-2185

145. Schroeck FR, Sun L, **Freedland SJ**, Jayachandran J, Robertson CN, and Moul JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. *Prost Cancer Prost Dis*, 2008;11: 371-376

146. Rampersaud E, Sun L, Moul JW, Madden J, and **Freedland SJ**. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. *J Urol*, 2008;180: 571-576

147. Trock BJ, Han M, **Freedland SJ**, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival in men with biochemical recurrence after radical prostatectomy: impact of salvage radiation therapy vs. observation. *JAMA*, 2008;299: 2760-2769

148. Nelles JL, **Freedland SJ**, Presti JC Jr, Terris MK, Aronson WJ, Amling CL, and Kane CJ. Nerve sparing does not increase the risk of biochemical recurrence: results from the SEARCH database. *Prostate Cancer Prostatic Dis*, 2009;12: 172-176

149. **Freedland SJ**, Sun L, Kane CJ, Presti JC, Terris MK, Amling CL, Moul JW, and Aronson WJ. Obesity and oncological outcome after radical prostatectomy: impact of PSA-based prostate cancer screening: results from the SEARCH and Duke Prostate Center databases. *BJU Intl*, 2008;102: 969-974

150. Jayachandran J, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, and **Freedland SJ**. Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the SEARCH database. *BJU Intl*, 2008;102: 964-968

151. **Freedland SJ**, Wen J, Wuerstle M, Shah A, Lai D, Moalej B, Atala C, and Aronson WJ. Obesity is a significant risk factor for prostate cancer at the time of biopsy. *Urol*, 2008;72: 1102-1105

152. Hamilton RJ and **Freedland SJ**. Rationale for Statins in the Chemoprevention of Prostate Cancer. *Curr Urol Reports*, 2008;9: 189-196
153. Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr., Amling CL, and **Freedland SJ**. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the SEARCH database. *BJU Intl*, 2008;102: 1980-1984
154. Teeter AE, Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ and **Freedland SJ**. What are the factors associated with a short PSA doubling time? Report from the SEARCH database group. *J Urol*, 2008;180: 1511-1518
155. Hamilton RJ, Goldberg KC, Platz EA, and **Freedland SJ**. The influence of statin medications on prostate specific antigen levels in healthy men. *JNCI*, 2008;100: 1511-1518
156. **Freedland SJ**. PSA kinetics and surrogacy: ready for prime time? *Lancet Onc*, 2008;9: 1025-1026
157. Schroeck FR, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? *BJU Intl*, 2009;103: 603-608
158. Wong Y, **Freedland SJ**, Hudes G, Schwartz JS, Mitra N, and Armstrong K. The role of androgen deprivation therapy in node positive prostate cancer. *J Clin Onc*, 2009;27:100-105
159. Moul JW, Sun L, and **Freedland SJ**. Clinical and pathological characteristics of prostate cancer: analysis of the Duke Prostate Center (DPC) and SEARCH Databases. *Grand Rounds in Urol*, 2009;8: 6-9
160. Gross M, Nepomuceno E, Luthringer D, Vollmer RT, Burchette J Jr, and **Freedland SJ**. Androgen receptor and estrogen receptor beta associates with Gleason score, but not obesity, in prostate cancer. *Prostate*, 2009;69: 520-527
161. Antonelli J, **Freedland SJ**, and Jones, LW. Exercise therapy across the prostate cancer continuum. *Pros Can Pros Dis*, 2009;12: 110-115
162. Shah SR, **Freedland SJ**, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, and Terris MK. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. *BJU Intl*, 2009;103: 1168-1172
163. **Freedland SJ** and Aronson WJ. Dietary intervention strategies to modulate prostate cancer risk and prognosis. *Current Opinion in Urol*, 2009;19: 263-267
164. Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ, and **Freedland SJ**. Preoperative predictors of blood loss at the time of radical prostatectomy: results from the SEARCH database. *Pros Can Pros Dis*, 2009;12: 264-268

165. Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Race and time from diagnosis to radical prostatectomy: does equal-access mean equal timely access to the operating room? - results from the SEARCH database. *Cancer Epi Biomarkers Prev*, 2009;18: 1208-1212

166. Hamilton RJ, Platz EA, and **Freedland SJ**. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker. *J Natl Can Inst*, 2009;101: 611-612

167. Lyman GH, Kuderer NM, and **Freedland SJ**. Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding. *J Natl Cancer Inst*, 2009;101: 543-545

168. Wong YN, **Freedland SJ**, Egleston B, Vapiwala N, Uzzo R, and Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. *Eur Urol*, 2009;56: 609-616

169. **Freedland SJ** and Aronson WJ. Lower urinary tract symptoms and inflammation: weighing the evidence. *Am. J Epi*, 2009;169: 1291-1293

170. Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrnyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, **Freedland SJ**, Vollmer RT, Albertsen P, Costa J, and Codon-Cardo C. Personalized prediction of tumor response and cancer progression on prostate needle biopsy. *J Urol*, 2009;182: 125-132

171. Moreira DM, Jayachandran J, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Stephenson AJ, and **Freedland SJ**: Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH Database. *BJU Intl*, 2009;104: 1452-1456

172. Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi GR, Demark-Wahnefried W, Westman EC, Peterson BL, Johnson T, Pizzo SV, and **Freedland SJ**. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. *Can Prev Res*, 2009;2: 557-565

173. Jayachandran J and **Freedland SJ**. Prevention of prostate cancer: what we know and where we are going. *Amer J Mens Health*, 2008;2: 178-189

174. Jones LW, Eves ND, Haykowsky M, **Freedland SJ**, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. *Lancet Oncology*, 2009;10: 598-605

175. Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**: Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: Results from the SEARCH Database. *BJU Intl*, 2010;105: 28-33

176. Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Moul JW, and **Freedland SJ**. Body mass index and prostate specific antigen as a predictor of adverse pathology of prostate cancer and biochemical recurrence following radical prostatectomy. *J Urol*, 2009;182: 491-496

177. Teeter AE, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Does early PSADT, calculated starting at the first detectable PSA after radical prostatectomy, correlate with standard PSADT?—a report from the SEARCH database group. *BJU Intl*, 2009;104: 1604-1609

178. **Freedland SJ**, Bañez LL, Sun L, Fitzsimons N, and Moul JW. Obese men have higher-grade and larger tumors: an analysis of the Duke Prostate Center Database. *Pros Can Pros Dis*, 2009;12: 259-263

179. Jayachandran J, Bañez LL, Levy D, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, and **Freedland SJ**. Obesity as a predictor of adverse outcome across black and white race: results from the shared equal access regional cancer hospital (SEARCH) database. *Cancer*, 2009;115: 5263-5371

180. Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ, and **Freedland SJ**. Estimated blood loss as a predictor of PSA recurrence: Results from the SEARCH database, *BJU Intl*, 2010;105: 347-351

181. Jayachandran J, Schroeck F, Sun L, Gerber L, Moreira D, Moul JW, and **Freedland SJ**. The shared equal access regional cancer hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke prostate center (DPC) database. *BJU Intl*, 2010;105: 180-184

182. **Freedland SJ**. Editorial Comment. *Urol*, 2009;74: 516

183. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**: Natural history of patients with persistently elevated PSA after radical prostatectomy: Results from the SEARCH Database. *J Urol*, 2009;182: 2250-2256

184. Antonelli J, Jones LW, Bañez LL, Thomas JA, Anderson K, Taylor LA, Gerber L, Crowe N, Anderson T, Hoyo C, Grant D, and **Freedland SJ**. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. *J Urol*, 2009;182: 2226-2231

185. Roobol MJ, Schröder FH, Crawford ED, **Freedland SJ**, Sartor AO, Fleshner N, and Andriole GL. A framework for the identification of men at increased risk of developing prostate cancer. *J Urol*, 2009;182: 2112-2122

186. Chang SL, **Freedland SJ**, Terris MK, Aronson WJ, Kane CJ, Amling CL, and Presti JC Jr. Freedom from a detectable ultrasensitive PSA at two years after radical prostatectomy predicts a favorable clinical outcome: Analysis of the SEARCH database. *Urol*, 2010;2: 439-444

187. **Freedland SJ**, William CD, and Masko EM. Adiponectin and prostate cancer mortality: To be or not to be skinny? *Clin Chem*, 2010;56: 1-3

188. **Freedland SJ**, Eastham J, and Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. *Pros Can Pros Dis*, 2009;12: 333-338
189. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**: Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the SEARCH Database. *BJU Intl*, 2010;105: 1541-1547
190. Schroeck FR, Kattan MW, Moul JW, Aronson WJ, Presti Jr. JC, Terris MK, Kane CJ, Amling CL, Sun L and **Freedland SJ**. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. *BJU Intl*, 2010;105: 1654-9
191. Aronson WJ, Barnard RJ, **Freedland SJ**, Henning S, Elashoff D, Jardack P, Cohen P, Heber D, and Kobayashi N. Growth inhibitory effect of a low-fat diet on prostate cancer cells: results of a prospective randomized dietary intervention trial in men with prostate cancer. *J Urol*, 2010;183: 345-350
192. Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Sun LL, Moul JW, and **Freedland SJ**. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. *Prost Can Pros Dis*, 2010;13: 87-93
193. Jones LW, Viglanti BL, Tashjian JA, Kothadia S, Keir ST, **Freedland SJ**, Potter MQ, Moon EJ, Herndon JE, II, Dewhirst MW. Effect of voluntary wheel running exercise on tumor metabolism and angiogenesis in an orthotopic model of human breast cancer. *J Applied Physiology*, 2010;108: 343-348
194. Keating NL, O'Malley AJ, **Freedland SJ**, and Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. *J Natl Cancer Inst*, 2010;102: 39-46
195. **Freedland SJ** and Aronson WJ. Words of wisdom: re: Weight Loss with a low-carbohydrate, Mediterranean, or low-fat diet. *Eur Urol*, 2009;55: 249-250
196. Jayachandran J, Aronson WJ, Terris MK, Presti JC, Jr., Amling CL, Kane CJ, and **Freedland SJ**. Diabetes and outcomes after radical prostatectomy – are results affected by obesity and race? Results from the SEARCH database. *Can Epi Bio Prev*, 2010;19: 9-17
197. Mondul AM, Selvin E, De Marzo, **Freedland SJ**, and Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. *Cancer Causes Cont*, 2010;21: 671-678

198. Masko EM, Bañez LL, and **Freedland SJ**. Words of wisdom: re: Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. *Eur Urol*, 2010;57: 542-543
199. Teeter AE, Sun L, Moul JW, and **Freedland SJ**. External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database. *BJU Intl*, 2010;106: 796-800
200. Bañez LL, Klink J, Jayachandran J, Lark A, Gerber L, Hamilton RJ, Masko EM, Vollmer RT, and **Freedland SJ**. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. *Cancer Epi Bio Prev*, 2010;19: 722-728
201. Buschemeyer WC, Klink J, Mavropoulos JC, Poulton SH, Demark-Wahnefried W, Hursting SD, Cohen P, Hwang D, Johnson TL, and **Freedland SJ**. Effect of intermittent caloric restriction on prostate cancer growth and survival in SCID mice. *Prostate*, 2010;70: 1037-1043
202. Lloyd JC, Antonelli J, Masko EM, Thomas JA, Phillips TE, Poulton SH, Pollak M, and **Freedland SJ**. Effect of isocaloric low-fat diet on prostate cancer xenograft progression in a hormone-deprivation model. *J Urol*, 2010;183: 1619-1624
203. Bañez LL, Loftis RM, **Freedland SJ**, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, and Terris MK. The influence of hepatic dysfunction on prostate cancer outcomes following radical prostatectomy. *Prost Cancer Prost Dis*, 2010;13: 173-177
204. Bañez LL and **Freedland SJ**. Editorial comment. *Urol*, 2010;75: 652-653
205. Moreira DM, Bañez LL, and **Freedland SJ**. Editorial comments. *J Urol*, 2010;183: 1796
206. Gerber L, Bañez LL, and **Freedland SJ**. Defining and treating high-risk prostate cancer: can we do better? *Eur Urol*, 2010;58: 8-9
207. Moreira DM, Antonelli JA, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Association of cigarette smoking with time to biochemical recurrence after radical prostatectomy: Results from the SEARCH Database. *Urol*, 2010;76: 1218-1223
208. Kane CJ, Im R, Amling CL, Presti JC Jr., Aronson WJ, Terris MK, and **Freedland SJ**. Outcomes after radical prostatectomy among men who are candidates for active surveillance: Results from the SEARCH database. *Urol*, 2010;76: 695-700
209. Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, **Freedland SJ**, Ittmann MM, Lark AL, Madden JF, Hartman A, Weiss G, and Castaños-Vélez E. Multicenter clinical validation of PITX2 methylation as a predictor of PSA recurrence in post-radical prostatectomy prostate cancer patients. *J Urol*, 2010;184: 149-156
210. Hamilton RJ, Bañez LL, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr., Amling CL, and **Freedland SJ**. Statin medication use and the risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. *Cancer*, 2010;116: 3389-3398

211. Tang P, Sun L, Uhlman M, Polascik TJ, **Freedland SJ**, and Moul JW. Baseline PSA as a predictor of prostate cancer specific mortality over the past 2 decades: Duke University experience. *Cancer*, 2010;116: 4711-4717

212. Kim H and **Freedland SJ**. Androgen deprivation therapy in prostate cancer: anticipated side effects and their management. *Curr Opin Supp & Pall Care*, 2010;4: 147-152

213. Kim H, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Glycemic control and prostate cancer progression: results from the SEARCH database. *Prostate*, 2010;70:1540-1546

214. Masko EM, Thomas JA, Antonelli JA, Lloyd JC, Phillips TE, Poulton SH, Dewhirst MW, Pizzo SV, and **Freedland SJ**. Low-carbohydrate diets and prostate cancer: how low is “low-enough”? *Cancer Prev Res*, 2010;3: 1124-1131

215. Thomas JA, II, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M, and **Freedland SJ**. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. *Pros Can Pros Dis*, 2010;13: 350-355

216. Vickers A, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan M, Klein E, Hamdy F, Neal D, Donovan J, Parekh D, Ankerst D, Bartsch G, Klocker H, Benchikh A, Salama G, **Freedland SJ**, Moreira DM, Schroder FH, and Lilja H. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. *Clin Cancer Res*, 2010;16: 4374-4381

217. Chu DI and **Freedland SJ**. Prostate cancer: Socioeconomic status as a predictor of prostate cancer treatment pattern. *Nature Rev Urol*, 2010;7: 480-481

218. Kim H, Moreira DM, Smith MR, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. A natural history of weight change in men with prostate cancer on androgen deprivation therapy: results from the SEARCH database. *BJU Intl*, 2011;107: 924-928

219. Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Postoperative PSA nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: results from the SEARCH database. *Int J Urol*, 2010;17: 914-922

220. Chun FK, Epstein JI, Ficarra B, **Freedland SJ**, Montironi R, Montorsi S, Shariat SF, Schroder FH, and Scattoni V. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. *Eur Urol*, 2010;58: 851-864

221. **Freedland SJ**. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. *Cancer*, 2011;117: 1123-1135

222. Thomas JA, Bañez LL, and **Freedland SJ**. Editorial Comment: Sex hormones and the risk of incident prostate cancer. *Urol*, 2010;75: 1040-1041

223. **Freedland SJ**. Editor's comments. *Pros Can Pros Dis*, 2010;13: 295
224. Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TLJ, Teloken C, Tindall D, **Freedland SJ**, Somerville MC, Wilson TH, Fowler I, Castro R, and Rittmaster RS. The effect of dutasteride on the utility of PSA for the diagnosis of high-grade and clinically relevant prostate cancer in men with a previous negative biopsy: Results from the REDUCE study. *J Urol*, 2011;185: 126-131
225. **Freedland SJ** and Andriole GL. Making an imperfect marker better. *Eur Urol*, 2011;59: 194-196
226. Teeter AE, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Does PSADT after radical prostatectomy correlate with overall survival and prostate cancer-specific mortality? A Report from the SEARCH Database Group. *Urol*, 2011;77: 149-153
227. Stewart SB and **Freedland SJ**. Influence of obesity on the incidence and treatment of genitourinary malignancies. *Sem Urol Onc*, 2011; 29:476-86
228. Chu DI and **Freedland SJ**. Editorial comment. *Urol*, 2011;77: 141-142
229. Thomas JA and **Freedland SJ**. Obesity and prostate cancer: collateral damage in the battle of the bulge. *Front Biosciences*, 2011;3: 594-605
230. Keto CJ and **Freedland SJ**. A risk-stratified approach to PSA screening. *Eur Urol*, 2011;59: 506-508
231. Williams CD, Whitley BM, Hoyo C, Grant DJ, Iraggi JD, Newman KA, Gerber L, Taylor LA, McKeever MG, and **Freedland SJ**. A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased prostate cancer risk. *Nutrition Research*, 2011;31: 1-8
232. Saylor PJ, Keating NL, **Freedland SJ**, and Smith MR. Gonadotropin releasing hormone (GnRH) agonists and the risks of diabetes and cardiovascular. *Drugs*, 2011;71: 255-261
233. Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, **Freedland SJ**, Walsh PC and Platz EA. Weight gain is associated with an increased risk of prostate cancer recurrence in the PSA era. *Cancer Prev Res*, 2011;4: 544-551
234. De Nunzio C, **Freedland SJ**, Miano R, Truccki A, Cantiani A, Carluccine A, Tubaro A. Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. *Prostate*, 2011;71: 1492-1498
235. Armstrong AJ, **Freedland SJ**, and Garcia-Blanco M. Epithelial-mesenchymal transition in prostate cancer: providing new targets for therapy. *Asian J Andr*, 2011;13: 179-180
236. Masko EM and **Freedland SJ**. Prostate cancer and diet: food for thought? *BJU Intl*, 2011;107: 1359-1360

237. Kim HS, Moreira DM, Jayachandran J, Gerber L, Bañez LL, Vollmer R, Lark A, Donovan M, Powell D, Khan F and **Freedland SJ**. Prostate biopsies from African-American men express higher levels of aggressive disease biomarkers than prostate biopsies from Caucasian men. *Pros Can Pros Dis*, 2011;14: 262-265
238. Chu DI and **Freedland SJ**. Metabolic risk factors in prostate cancer. *Cancer*, 2011;117: 2020-2023
239. Moreira DM, Anderson T, Gerber L, Thomas JA, Bañez LL, McKeever MG, Hoyo C, Grant D, Jayachandran J, and **Freedland SJ**. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. *Cancer Causes Control*, 2011;22: 977-983
240. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, **Freedland SJ**, Erbersdobler A, van der Kwast TH. The contemporary concept of significant versus insignificant prostate cancer. *Eur Urol*, 2011;60: 291-303
241. Marberger M, **Freedland SJ**, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R. Usefulness of PSA rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. *BJU Intl*, 2012; 109:1162-9
242. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL and **Freedland SJ**. Diabetes and prostate cancer risk in the REDUCE trial. *Pros Cancer Prost Dis*, 2011;14: 326-331
243. Chu DI, De Nunzio C, Gerber L, Thomas JA, Calloway E, Albisinni S, McKeever MG, Moreira DM, Tubaro A, Moul JW, **Freedland SJ**, and Bañez LL. Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. *Pros Can Pros Dis*, 2011;14: 346-353
244. Kopp RP, Han M, Partin AW, Humphreys E, **Freedland SJ** and Parsons JK. Obesity and prostate enlargement in men with localized prostate cancer. *BJU Intl*, 2011;108: 1750-1755
245. Kopp RP, **Freedland SJ**, and Parsons JK. Associations of benign prostatic hyperplasia with prostate cancer: the debate continues. *Eur Urol*, 2011;60: 699-700
246. **Freedland SJ**. Editor's comments. *Pros Cancer Prost Dis*, 2011;14: 191
247. Keto CJ, Masko EM, and **Freedland SJ**. Physical activity, obesity, and LUTS. *Eur Urol*, 2011;60: 1181-1183
248. Auprich M, Bjartell A, Chun F, **Freedland SJ**, Haese A, Montorsi F, van der Poel H, Schalken J, Stenzl A, de la Taille A, Tombal B. Contemporary role of PCA3 in the management of prostate cancer. *Eur Urol*, 2011;60: 1045-1054
249. Whitley BM, Moreira DM, Thomas JA, Aronson WJ, Terris MK, Presti JC, Jr., Kane CJ, Amling CL, **Freedland SJ**. Preoperative weight change and risk of adverse outcome

following radical prostatectomy: results from the shared equal access regional cancer hospital (SEARCH) database. *Pros Can Pros Dis*, 2011;14: 361-366

250. Hamilton RJ and **Freedland SJ**. 5-alpha reductase inhibitors and prostate cancer prevention: where do we turn now? *BMC-Medicine*, 2011;9:105

251. De Nunzio C, Albisinni S, **Freedland SJ**, Miano L, Cindolo L, Agro EF, Autorino R, DeSio M, Schips L, and Tubaro A. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study. *Urol Onc*, 2013; 31:997-1002

252. De Nunzio C, **Freedland SJ**, Minao L, Agro EF, Bañez LL, Tubaro A. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis. *Eur J Surg Onc*, 2011;37: 1025-1039

253. Ho T, Bañez LL, and **Freedland SJ**. Editorial Comment, *Urol*, 2011;78: 872-873

254. Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, Liu B, Gray A, Wan J, Konijeti R, **Freedland SJ**, Castor B, Heber D, Elashoff D, Said J, Cohen P, Galet C. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. *Cancer Prev Res*, 2011;4: 2062-2071

255. Stewart S, Bañez L, Xie D, **Freedland SJ**, Robertson C, Polascik T, Walther P, Koontz B, Vujaskovic Z, Lee R, Armstrong A, Febbo P, George D and Moul J. Utilization trends of a multidisciplinary prostate cancer clinic: Initial 5-year experience from the Duke Prostate Center. *J Urol*, 2012;187: 103-108

256. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, and **Freedland SJ**. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: Results from the SEARCH database. *BJU Intl*, 2012;110: 492-498

257. De Nunzio C, Aronson WJ, **Freedland SJ**, Giovannucci E, and Parson KJ. The correlation between metabolic syndrome and prostatic disease. *Eur Urol*, 2012;61: 560-570

258. So C, Kirby KA, Mehta K, Hoffman RM, Powel AA, **Freedland SJ**, Sirovich B, Yano EM, and Walter LC. Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy. *J Gen Internal Med*, 2012;27: 653-660

259. Kimura M, Bañez LL, Gerber L, Qi J, Tsivian M, **Freedland SJ**, Satoh T, Polascik TJ, Baba S, and Moul JW. Association between preoperative erectile dysfunction and prostate cancer features - an analysis from the Duke Prostate Center database. *J Sex Med*, 2012;9: 1174-1181

260. Roobol MJ, Schroder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, **Freedland SJ**, Moreira DM, Vickers AJ, Lilja H, and Steyerberg EW. Importance of prostate volume in the European Randomized Study of Screening for Prostate

Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. *World J Urol*, 2012;30: 149-155

261. Ankerst DP, Boeck A, **Freedland SJ**, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, and Vickers AJ. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. *World J Urol*, 2012;30: 181-187

262. Thomas JA II, Gerber L, Moreira DM, Hamilton RJ, Bañez LL, Castro-Santamaria R, Andriole GL, Isaacs WB, Xu J, and **Freedland SJ**. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study. *J Int Med*, 2012;272: 85-92

263. Williams CD, Whitley BM, Hoyo C, Grant DJ, Schwartz GG, Presti JC, Iraggi JD, Newman KA, Gerber L, Taylor LA, McKeever MG, and **Freedland SJ**. Dietary calcium and risk of prostate cancer: a case-control study in veterans. *Preventing Chronic Disease*, 2012;9:E39

264. Nambudiri VE, Landrum MB, Lamont EB, McNeil BJ, Bozeman SR, **Freedland SJ**, Keating NL. Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. *Urol*, 2012;79:537-545

265. Thomas JA II, Gerber L, Bañez L, Moreira D, Rittmaster RS, Andriole GL, and **Freedland SJ**. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE study. *Cancer Epi Bio Prev*, 2012;21: 576-581

266. **Freedland SJ** and Walter LC. 80 is the new 60: Implications of irrational exuberance regarding longevity on prostate cancer treatment decisions. *J Gen Int Med*, 2012;27: 485-486

267. Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, **Freedland SJ**, Montorsi F, Roach M 3rd, Schroder F, van Poppel H, Stief CG, Stephenson AJ, and Zelefsky MJ. High-risk prostate cancer: from definition to contemporary management. *Eur Urol*, 2012;61: 1096-1106

268. Kim HS, Masko EM, Poulton SL, Kennedy KM, Pizzo SV, Dewhirst MW, and **Freedland SJ**. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. *BJU Intl*, 2012;110: 1062-1069

269. Chu DI, Moreira DM, Gerber L, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access healthcare setting: results from the SEARCH database. *Cancer*, 2012;118: 4999-5007

270. Muller RL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. *Urol*, 2012;79: 1105-1110

271. **Freedland SJ**. European Urology – an American Perspective. *Eur Urol*, 2012;61: 1197-1198

272. Osmond GW, Masko EM, Tyler DS, **Freedland SJ**, and Pizzo S. *In vitro* and *in vivo* evaluation of resveratrol and 3,5-dihydroxy-4-acetoxy-*trans*-stilbene in the treatment of human prostate carcinoma and melanoma. *J Surg Res*, 2013;179: e141-148
273. Moreira DM, Gerber L, Thomas JA, Bañez LL, McKeever MG and **Freedland SJ**. Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy. *Int J Urol*, 2012;19: 741-747
274. Kopp R, Stroup SP, Schroeck F, **Freedland SJ**, Millard F, Terris MK, Aronson WJ, Presti JC Jr., Amling CL, and Kane CJ. Are repeat biopsies safe? A cohort analysis from the SEARCH Database. *J Urol*, 2012;187: 2056-2060
275. Abern MR, Allott EH, and **Freedland SJ**. Editorial comment: C-reactive protein as a prognostic marker for mCRPC. *BJU Intl*, 2012; 110:E469
276. Hamilton RJ, Andriole GL, and **Freedland SJ**. 5-alpha reductase inhibitors: preventing the treatable. *Eur Urol*, 2012;62: 242-244
277. Ankerst DP, Boeck A, **Freedland SJ**, Jones JS, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ, and Thompson IM. Evaluating the Prostate Cancer Prevention Trial high grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. *World J Urol*, 2014;32: 185-91
278. Keating NL, O'Malley AJ, **Freedland SJ**, and Smith MR. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen deprivation therapy for prostate cancer? *Eur Urol*, 2013;64: 159-66
279. Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, Dewhirst MW, Dyck JRB, Nagendran J, Flores CT, Betof AS, Nelson ER, Pollak M, Dash RC, Young ME, and **Freedland SJ**. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. *J App Physiol*, 2012;113: 263-272
280. Albisinni S, De Nunzio C, Tubaro A, Bañez LL, and **Freedland SJ**. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. *Urol*, 2012;80: 162-168
281. Muller RL, Gerber L, Moreira DM, Andriole G, Castro R, and **Freedland SJ**. Serum testosterone and dihydrotestosterone levels and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. *Eur Urol*, 2012;62: 757-764
282. Choudhury AD, Eeles R, **Freedland SJ**, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T. The role of genetic markers in the management of prostate cancer. *Eur Urol*, 2012;62: 577-587

283. Dall'era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Copperberg MR, **Freedland SJ**, Klotz LH, Parker C, and Soloway MS. Active surveillance for prostate cancer: A systematic review of the literature. *Eur Urol*, 2012;62: 976-983
284. Abern MR, **Freedland SJ**, and Inman BA. Editorial comment: Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. *BJU Intl*, 2013;111: 187-188
285. **Freedland SJ**, Richhariya A, Wang H, Chung K, and Shore ND. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. *Urol*, 2012;80: 293-298
286. Muller RL, Faria EF, Carvalhal GF, Reis RB, Mauad EC, Carvalho AL, and **Freedland SJ**. Association between family history of prostate cancer and positive biopsies in a Brazilian screening program. *World J Urol*, 2013;31: 1273-8
287. Bañez LL, Albisinni S, **Freedland SJ**, Tubaro A, and De nunzio C. The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. *World J. Urol*, 2014;32: 323-8
288. Ho T, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, and **Freedland SJ**. Obesity, PSA nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. *Eur Urol*, 2012;62: 910-916
289. Vidal A, Grant DJ, Williams CD, Masko E, Allott EH, Shuler K, McPhail M, Gaines AR, E Calloway, Gerber L, Chi JT, **Freedland SJ**, and Hoyo C. Associations between intake of folate, methionine, and vitamins B-12, B-6 and prostate cancer risk in American veterans. *J Cancer Epi*, 2012;2012: 957467
290. Bolenz C, **Freedland SJ**, Hollenbeck BK, Lotan Y, Lowrance WT, Nelson JB, and Hu JC. Costs of radical prostatectomy for prostate cancer: a systematic review. *Eur Urol*, 2014;65: 316-24
291. Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC. Jr, Amling CL, and **Freedland SJ**. Delayed radical prostatectomy in intermediate-risk prostate cancer decreases time to biochemical recurrence: results from the SEARCH Database. *Prostate*, 2013;73: 409-417
292. Abern M and **Freedland SJ**. PCA3 to select men for prostate biopsy: stop, go, or proceed with caution? *Eur Urol*, 2013;63: 210-211
293. Ukimura O, Coleman J, de la Taille A, Emberton M, Epstein JI, **Freedland SJ**, Giannarini G, Kibel A, Montironi R, Ploussard G, Roobol M, Scattoni V, Jones JS. Contemporary role of systematic prostate biopsies: indications, technique, implications on patient care. *Eur Urol*, 2013;63: 214-230
294. Caso J, Masko EM, Thomas JA II, Poulton SH, Dewhirst M, Pizzo SV, and **Freedland SJ**. The effect of carbohydrate restriction on prostate cancer growth in a castrate mouse xenograft model. *Prostate*, 2013;73: 449-54

295. Abern MR, Basset MR, Tsivian M, Bañez LL, Polascik TH, Ferrandino MN, Robertson CN, **Freedland SJ**, and Moul JW. Race is associated with discontinuation of active surveillance of low-risk prostate cancer – results from the Duke Prostate Center. *Pros Can Prost Dis*, 2013;16: 85-90
296. Moghanaki D, **Freedland SJ**, and Anscher M. Re: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis. *Int J. Urol*, 2013;20: 547-8
297. Grant DJ, Hoyo C, Oliver SD, Gerber L, Shuler K, Calloway E, Livingston JN, Richardson RM, Schildkraut JM, Gaines AR, McPhail M, and **Freedland SJ**. Association of UDP-glucuronosyltransferase 2B gene variants with serum glucuronide levels and prostate cancer risk. *Genetic Testing and Molecular Biomarkers*, 2013;17: 3-9
298. **Freedland SJ**. Editor's comments. *Prost Can Prost Dis*, 2012;15: 313
299. Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst M, Pizzo SV, and **Freedland SJ**. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. *Prostate*, 2013;73: 754-62
300. Saylor PJ, Armstrong AJ, Fizazi K, **Freedland SJ**, Saad F, Smith MR, Tombal B, and Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. *Eur Urol*, 2013;63: 309-320
301. Allott EH and **Freedland SJ**: Re: impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. *Eur Urol*, 2013;63: 178-179
302. Masko EM, Allott EH, and **Freedland SJ**. The relationship between nutrition and prostate cancer: is more always better? *Eur Urol*, 2013;63: 810-20
303. Allott EH, Masko EM, and **Freedland SJ**. Obesity and prostate cancer: weighing the evidence. *Eur Urol*, 2013;63: 800-9
304. Keto CJ, Aronson WJ, Terris MK, Presti JC Jr. Kane CJ, Amling CL, and **Freedland SJ**. Detectable PSA nadir during androgen deprivation therapy predicts adverse prostate cancer specific outcomes: Results from the SEARCH database. *Eur Urol*, 2014;65: 620-7
305. Dietrich D, Hasinger O, Bañez LL, Sun L, van Leenders GL, Wheeler TM, Bangma CH, Wernert N, Perner S, **Freedland SJ**, Corman J, Ittmann MM, Lark AL, Madden JF, Hartmann A, Schatz P, Kristiansen G. Development and clinical validation of a real-time PCR assay for *PITX2* DNA methylation to predict PSA recurrence in prostate cancer patients following radical prostatectomy. *J. Molecular Diagnostics*, 2013;15: 270-9
306. Wu C, Aronson WJ, Terris MK, Presti JC Jr., Kane CJ, Amling CL, and **Freedland SJ**. Diabetes predicts metastasis after radical prostatectomy, but only in obese men: results from the SEARCH database. *BJU Intl*, 2013;111: E310-8

307. Reply from authors. Hu JC, **Freedland SJ**, Hollenbeck BK, Lotan Y, Lowrance WT, Nelson JB, and Bolenz C. *Eur Urol*, 2014;65: 327-8
308. Singh A, Jones L, Antonelli J, Gerber L, Calloway E, Shuler K, **Freedland SJ**, Grant D, Hoyo C, and Bañez L. Association between exercise and primary incidence of prostate cancer—does race matter? *Cancer*, 2013;119: 1338-43
309. Beebe-Dimmer J and **Freedland SJ**. ADT: further confirmation of known harms. *BJUI*, 2013;111: 690-1
310. van den Bergh RCN, Albertsen PC, Bangma CH, **Freedland SJ**, Graefen M, Vickers A, van der Poel HG. Timing of curative treatment for prostate cancer: A systematic review. *Eur Urol*, 2013;64: 204-15
311. Keating NL, Liu PH, O'Malley AJ, **Freedland SJ**, and Smith MR. Androgen deprivation therapy and diabetes control among diabetic men with prostate cancer. *Eur Urol*, 2014;65: 816-24
312. Ross SS*, Masko EM*, Abern MR, Allott EH, Routh JC, Wiener JC, Preminger GM, **Freedland SJ**** and Lipkin ME**. The effect of dietary sodium and fructose intake on urine and serum parameters of stone formation in a pediatric mouse model: a pilot study. *J Urol*, 2013;190: 1484-9
313. Thomas JA II, Antonelli J, Bañez L, Hoyo C, Grant DJ, Demark-Wahnefried W, Platz EA, Gerber L, Shuler K, Calloway E, Eyoh E, and **Freedland SJ**. Androgenetic alopecia at various ages and prostate cancer risk in an equal access multiethnic case control series of veterans. *Cancer Causes and Control*, 2013;24: 1045-52
314. Muller RL, Gerber L, Moreira DM, Andriole G, Fleshner N, Parsons JK, Hamilton RJ, and **Freedland SJ**. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. *Eur Urol*, 2013;63: 1115-21
315. Klink JC, Bañez LL, Jayachandran J, Gerber L, Lark A, Vollmer RT, and **Freedland SJ**. Intratumoral inflammation is associated with more aggressive prostate cancer. *World J Urol*, 2013;31: 1497-503
316. Mithal P and **Freedland SJ**. Editorial comment. *Urol*, 2013;81: 1208
317. **Freedland SJ**, Hamilton RJ, Gerber L, Bañez LL, Moreira DM, Andriole GL, and Rittmaster RS. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. *Pros Can Pros Dis*, 2013;16: 254-9
318. Punnen S, **Freedland SJ**, Presti, JC, Jr., Aronson WA, Terris MK, Kane CJ, Amling CL, Carroll PR, and Cooperberg MR. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. *Eur Urol*, 2014;65: 1171-7

319. Walter LC, Zung K, Kirby K, Shi Y, Espaldon R, O'Brien S, **Freedland SJ**, Powell A, and Hoffman RM. 5-year downstream consequences following prostate specific-antigen (PSA) screening in older men. *JAMA Internal Medicine*, 2013;173: 866-73
320. Solomon KR, Allott EH, Freeman MR, and **Freedland SJ**. Re: Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. *Eur Urol*, 2013;63: 1128-9
321. Karlin J, Koontz B, **Freedland SJ**, Moul J, Grob B, Wan W, Hagan M, Anscher M, Moghanaki D. Identifying appropriate patients for very early salvage radiotherapy after prostatectomy. *J Urol*, 2013;190: 1410-5
322. Carter HB, Albertsen PC, Barry MJ, Etzioni R, **Freedland SJ**, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, and Zietman AL. Early detection of prostate cancer: AUA Guideline. *J Urol*, 2013;190: 419-26
323. Trinh QD, Bjartell A, **Freedland SJ**, Hollenbeck BK, Hu JC, Shariat SF, Sun M, and Vickers AJ. A systematic review of the volume-outcome relationship for radical prostatectomy. *Eur Urol*, 2013;64: 786-98
324. Cookson MS, Roth BJ, Dahm P, Engstrom C, **Freedland SJ**, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, and Kibel AS. Castration-resistant prostate cancer: AUA Guideline. *J Urol*, 2013;190: 429-38
325. Punnen S, Cooperberg MR, D'Amico AV, Karakiwicz PI, Moul JW, Scher HI, Schlomm T, and **Freedland SJ**. Management of biochemical recurrence after primary treatment of prostate cancer. *Eur Urol*, 2013;64: 905-15
326. **Freedland SJ**. Dietary fat and reduced prostate cancer mortality: Does the type of fat matter? *JAMA Int Med*, 2013;173: 1326-7
327. **Freedland SJ**, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, and Stone S. Prognostic utility of CCP score in prostate cancer after primary external beam radiation therapy. *Int J. Rad Bio Ther*, 2013;86: 848-53
328. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR?--A report from the SEARCH Database Group. *Urology*, 2013;82: 53-9
329. Teeter AE and **Freedland SJ**. Author response. *Urology*, 2013;82: 59
330. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, **Freedland SJ**, and Frenette PS. Autonomic tumour nerve development drives prostate cancer progression. *Science*, 2013;341: 6142

331. Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. High serum folate is associated with reduced biochemical recurrence after radical prostatectomy: Results from the SEARCH Database. *Int Braz J Urol*, 2013;39: 312-9

332. Lloyd JC, Masko EM, Wu C, Kirkpatrick M, Pilla D, Aronson WJ, Chi JTA, and **Freedland SJ**. Decreased mitochondrial and insulin pathway gene expression signal in a prostate cancer xenograft mouse model with varying dietary fat sources. *Pros Can Pros Dis*, 2013;16:285-91, corrigendum 2013;16: 398

333. Granieri MA and **Freedland SJ**. The interplay between obesity and the accuracy of PSA for predicting prostate cancer. *BJUI*, 2013;112: E272

334. Punnen S, Cooperberg MR, and **Freedland SJ**. Reply from the authors. *Eur Urol*, 2013;64: 918-9

335. Sridhar SS, **Freedland SJ**, Gleave ME, Higano C, Mulders C, Parker C, Sartor O, and Saad F. Castration-resistant prostate cancer: from new pathophysiology to new treatment. *Eur Urol*, 2014;65: 289-99

336. **Freedland SJ**, Carducci M, Kroeger N, Partin A, Rao JY, Jin Y, Kerkoutian S, Wu H, Li Y, Creel P, Mundy K, Gurganus R, Fedor H, King SA, Zhang Y, Heber D, Pantuck AJ. A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer prior to radical prostatectomy. *Can Prev Res*, 2013;6: 1120-7

337. Vidal A and **Freedland SJ**. Can we eat our way to a lower prostate cancer risk and if so, how? *Eur Urol*, 2014;65: 895-6

338. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, and **Freedland SJ**. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. *Prost Can Prost Dis*, 2013;16: 391-7

339. Taioli E, **Freedland SJ**, and Vidal A. Re: Low serum neutrophil count predicts a positive prostate biopsy. *Eur Urol*, 2013;64: 855-7

340. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, and **Freedland SJ**. Cigarette smoking is associated with increased risk for biochemical recurrence, metastasis, castration-resistant prostate cancer and mortality after radical prostatectomy: Results from the SEARCH Database. *Cancer*, 2014;120: 197-204

341. Vemana G, Hamilton RJ, Andriole GL, and **Freedland SJ**. Chemoprevention of prostate cancer. *Ann Rev in Med*, 2014;14: 111-23

342. Gollapudi K, Galet C, Grogan T, Zhang H, Pez GH, Said JW, Huang J, Elashoff D, Gerber L, **Freedland SJ**, Rettig M, and Aronson W. Tumor-associated macrophage infiltration is increased in prostate cancer but does not predict biochemical recurrence after radical prostatectomy. *Am J Can Res*, 2013;3: 523-9

343. Vidal A, Tucker C, Schildkraut JM, Richardson R, McPhail M, **Freedland SJ**, Hoyo C, and Grant DJ. Novel associations of UDP-glucuronosyltransferase 2B variants with prostate cancer risk in a multiethnic study. *BMC Cancer*, 2013;13: 556
344. Jones LW, Hornsby WE, **Freedland SJ**, Lane A, West MJ, Moul JW, Ferrandino MN, Allen JD, Kenjale AA, Thomas SM, Herndon JE, Koontz B, Chan JM, Khouri MG, Douglas PS, and Eves ND. Effects of non-linear aerobic training on erectile function and cardiovascular health following prostatectomy for clinical-localized prostate cancer. *Eur Urol*, 2014;65: 852-5
345. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, and **Freedland SJ**. Baseline prostate inflammation is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study. *Cancer*, 2014; 120:190-6
346. **Freedland SJ** and Stone S. In reply. *Int J Rad Onc Bio Phys*, 2014;88: 240-1
347. Crawford ED, Stone NN, Yu EY, Koo PJ, **Freedland SJ**, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, and Petrylak DP. Challenges and recommendations for early identification of metastatic disease in prostate cancer. *Urology*, 2014;83: 664-669
348. Moreira DM, Cooperberg MR, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Kuchibhatla M, and **Freedland SJ**. Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naïve men and patients receiving androgen deprivation therapy: Results from the SEARCH database. *Prost Can Prost Dis*, 2014;17: 91-6
349. McDonald AC, Vira MA, Vidal AC, Gan W, **Freedland SJ**, Taioli E. Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease – the 2001-2008 National Health and Nutrition Examination Survey. *Prost*, 2014;74: 561-7
350. Espaldon R, Kirby K, Fung K, Hoffman RM, Powell AA, **Freedland SJ**, and Walter LC. Probability of an abnormal screening prostate specific antigen (PSA) result based on age, race, and PSA threshold. *Urol*, 2014;83: 599-605
351. Vidal AC and **Freedland SJ**. Genetic variants in predicting aggressive prostate cancer: “ready for prime time?” *Eur Urol*, 2014;65: 1076-7
352. Bishoff JT, **Freedland SJ**, Gerber L, Tennstedt P, Reid J, Welbourn W, Graefen M, Sangale Z, Tikishvili E, Park J, Younus A, Gutin A, Lanchbury JS, Sauter G, Brawer M, Stone S, and Schlomm T. Prognostic utility of the CCP score generated from biopsy in men treated with prostatectomy. *J Urol*, 2014;192: 409-14
353. Fowke JH, Howard L, Andriole GL, and **Freedland SJ**. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE Trial. *Eur Urol*, 2014;66: 1133-8

354. Allott EA, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, **Freedland SJ**. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database. *BJUI*, 2014;114: 661-6
355. Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, and **Freedland SJ**. The impact of pathologic staging on the long term oncologic outcomes of clinically high risk prostate cancer. *Cancer*, 2014;120: 1656-62
356. Oh DS, Koontz B, **Freedland SJ**, Gerber L, Patel P, Lewis S, Yoo DS, Oleson JR, and Salama JK. Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy, *World J Urol*, 2015;33: 93-7
357. Chalfin HJ, Lee SB, Joeng BY, **Freedland SJ**, Feng Z, Trock BJ, Partin AW, Humphreys E, Walsh PC, and Han M. Obesity and long-term survival after radical prostatectomy. *J Urol*, 2014;192: 1100-4
358. Gaines AR, Turner EL, Moorman PG, **Freedland SJ**, Keto CJ, McPhail ME, Grant DJ, Vidal AC, and Hoyo C. The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort. *Cancer Causes Control*, 2014;25: 1029-35
359. Thomas JA, Gerber L, Hamilton RJ, Vidal AC, Moreira DM, Andriole GL, and **Freedland SJ**. Dutasteride and prostate cancer risk: does family history of prostate and/or breast cancers influence the number needed to treat? Results from REDUCE. *Am J Can Prev*, 2014;2:31-16
360. Sourbeer KN, Howard LE, Andriole GL, Moreira DM, Castro-Santamaria R, **Freedland SJ**, and Vidal AC. Metabolic syndrome-like components and prostate cancer risk: Results from the REDUCE Study. *BJU Intl*, 2015;115: 736-43
361. Stewart S, Moul JW, Polascik T, Koontz B, Robertson C, **Freedland SJ**, George D, Lee WR, Armstrong A, Bañez L. Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer? *Int J Urol*, 2014;21: 1215-9
362. Mithal P, Allott E, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Sangale Z, Lanchbury JS, Stone S, and **Freedland SJ**. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. *Int J Urol*, 2014;21: 1209-14
363. **Freedland SJ** and Mucci L. Is active surveillance safe for obese patients? *Nat Rev Urol*, 2014;11: 489-90
364. Ho T, Howard LE, Vidal AC, Gerber L, Moreira D, McKeever M, Andriole G, Castro-Santamaria R, and **Freedland SJ**. Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. *Clin Cancer Res*, 2014;20: 5331-8
365. Allott EH, Howard LE, Song HJ, Sourbeer KN, Koontz BF, Salama JK, **Freedland SJ**. Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiation therapy. *Cancer Epi Biom Prev*, 2014;23: 2404-12

366. Simon RM, **Freedland SJ**, Vidal AC. Identifying salvage radiotherapy failures: Are PSA response criteria the answer? *Int J Urol*, 2015;22: 88
367. Grill S, Fallah M, Leach RJ, Thompson IM, **Freedland SJ**, Hemminki K, and Ankerst DP. Incorporation of detailed family history from the Swedish family-cancer database into the Prostate Cancer Prevention Trial risk calculator. *J Urol*, 2015;193: 460-5
368. Islami F, Moreira DM, Boffetta P, and **Freedland SJ**. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. *Eur Urol*, 2014;66: 1054-64
369. Vidal AC, Howard LE, Moreira DM, Andriole GL, and **Freedland SJ**. Obesity increase the risk for high-grade prostate cancer: results from the REDUCE study. *Cancer Epi Biom Prev*, 2014;23: 2936-42
370. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, **Freedland SJ**. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. *Can Epi Biom Prev*, 2014;23: 2349-56
371. Jacobs EJ, Newton CC, Stevens VL, Campbell PT, **Freedland SJ**, and Gapstur SM. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with non-metastatic prostate cancer. *J Clin Onc*, 2014;32: 3716-22
372. **Freedland SJ**. The effect of diet and supplements on prostate cancer. *Clin Adv Hematol Onc*, 2014;12: 538-40
373. **Freedland SJ**, Rumble RB, Finelli A, Chen RC, Slovin S, Stein M, Mendelson D, Wackett C, and Sandler H. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. *J Clin Onc*, 2014;32: 3892-8
374. Mavropoulos JC, Hite AH, Howard LE, Vidal AC, Banez LL, Levine DM, Aronson WJ, Yancy WS, Westman EC, **Freedland SJ**. Comparison of low-carbohydrate vs. a low-fat diet on prostate cancer biomarkers. *J Trans Med Epi*, 2014;2: 1036
375. Lin PH and **Freedland SJ**. Lifestyle and LUTS: What is the correlation in men? *Current Opin in Urol*, 2015;25: 1-5
376. Vidal AC, Williams C, Allott EH, Howard LE, Grant D, McPahil M, Sourbeer KN, Lin PH, Boffetta P, Hoyo C, and **Freedland SJ**. Carbohydrate intake, glycemic index and prostate cancer risk. *Prostate*, 2015;75: 430-9
377. Shi Y, Fung KZ, **Freedland SJ**, Hoffman RM, Tang VL, Walter LC. Statin medications are associated with a lower probability of having an abnormal screening PSA result. *Urol*, 2014;84: 1058-65

378. **Freedland SJ**, Rumble RB, and Sandler H. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement summary. *J Onc Prac*, 2014;10: e415-7

379. Simon RM, Salama JK, and **Freedland SJ**. Radical prostatectomy vs. radiation therapy: can pre-treatment nomograms be used to select the appropriate prostate cancer treatment? *Eur Urol*, 2015;67: 210-1

380. Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BR, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, **Freedland SJ**. Practice patterns and predictors of follow-up imaging after a negative bone scan in men with CRPC: results from the SEARCH database. *J Urol*, 2015;193: 1232-8

381. Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, **Freedland SJ**. Is clinical stage T2C prostate cancer intermediate or high-risk disease? *Cancer*, 2015;121: 1414-21

382. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, and **Freedland SJ**. Aspirin, NSAID and risk of prostate cancer: Results from the REDUCE study. *Clin Can Res*, 2015;21: 756-62

383. Lin PH, Aronson WJ, and **Freedland SJ**. Nutrition, dietary interventions, and prostate cancer. *BMC Medicine*, 2015;13: 3

384. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, and **Freedland SJ**. Smoking is associated with acute and chronic prostatic inflammation: Results from the REDUCE study. *Can Prev Res*, 2015;8: 312-7

385. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, and **Freedland SJ**. Does obesity modify the ability of pre-biopsy PSA to detect prostate cancer on repeat biopsy? Results from the REDUCE study. *J Urol*, 2015;194: 52-7

386. Jatkoe TA, Karnes RJ, **Freedland SJ**, Wang Y, Le A, and Baden J. A urine-based methylation signature for risk stratification within low-risk prostate cancer. *BJC*, 2015;112: 802-8

387. Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, **Freedland SJ**. PSA, Stage, or Gleason Score: Which is best for predicting outcomes after radical prostatectomy and does it vary by the outcome being measured? results from SEARCH. *Int J Urol*, 2015;22: 362-6

388. Gerdtsen A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, **Freedland SJ**, Lilja H, and Ulmert D. Anthropometric measures at multiple times throughout life and prostate cancer diagnosis, metastasis, and death. *Eur Urol*, in press

389. Simon RM, Howard LE, Zapata D, Frank J, **Freedland SJ**, Vidal AC. The association of exercise with both erectile and sexual function in black and white men. *J Sex Med*, 2015;12: 1202-10
390. Jacobs EJ, Newton CC, Stevens VL, Campbell PT, **Freedland SJ**, Gapstur SM. Reply to M. Lee et al. *J Clin Onc*, 2015;33: 2226-7
391. Tang X, Keenan MM, Wu J, Lin CA, Dubois L, Thompson W, **Freedland SJ**, MurphySK, Chi JT. Comprehensive profiling of amino acid response uncovers unique methionine-deprived response dependent on intact creatine biosynthesis. *PLOS Genetics*, 2015;11: e1005158
392. Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, and **Freedland SJ**. Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the SEARCH Database. *Int J Urol*, 2015;22: 658-62
393. Moreira DM, Fleshner NE, **Freedland SJ**. Baseline perineural invasion is associated with shorter time to progression in men with prostate cancer undergoing active surveillance: Results from the REDEEM study. *J Urol*, 2015;194: 1258-63
394. Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, **Freedland SJ**, Abern MR. Agent Orange and long-term outcomes after radical prostatectomy. *Urol Onc*, 2015;33: 329.e1-6
395. Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling CL, **Freedland SJ**. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from SEARCH. *BJU Intl*, in press
396. Simon R, Howard LE, **Freedland SJ**, Aronson WJ, Terris MK, Kane CJ, Kane CJ, Amling CL, Cooperberg MR, Vidal AC. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? *BJU Intl*, in press
397. Vidal AC and **Freedland SJ**. Aspirin and prostate cancer prevention. *Aging*, 2015;7: 292-3
398. Ross A, D'Amico A, **Freedland SJ**. Which, when and why? Rational use of tissue based molecular testing in localized prostate cancer. *Prost Can Prost Dis*, in press
399. Klaassen Z, King SA, Li Q, Tatem AJ, Müller R, **Freedland SJ**, Madi R, Terris MK, Moses KA. Impact of comorbidity, race and marital status in men referred for prostate biopsy with PSA >20 ng/mL. *ISRN Urology*, in press
400. Moreira DM, Bostwick DG, Andriole GL, Peterson BL, Cohen HJ, Castro-Santamaria R, **Freedland SJ**. Baseline prostate atrophy is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy. *J Urol*, 2015;194: 1241-6

401. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Pratson CL, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, **Freedland SJ**. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. *Prost Can Prost Dis*, 2015;18: 333-7
402. Moreira DM, Nickel JC, Andriole GL, Castro-Santamaria R, **Freedland SJ**. Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study. *Prost*, 2015;75: 1492-8
403. Hoffman RM, Shi Y, **Freedland SJ**, Keating NL, Powell AA, Walter LC. Treatment patterns for older veterans with localized prostate cancer. *Cancer epi*, 2015;39: 769-77
404. Scott-Emuakpor J, Allot E, Johnson SA, Howard LE, Macias E, **Freedland SJ**, and Gurley SB. Angiotensin receptor signaling and prostate tumor growth in mice. *J Experimental Therapeutics and Oncology*, in press
405. Zapata D, MD, Howard LE, Allott EH, Hamilton RJ, Goldberg K, **Freedland SJ**. Is PSA related to serum cholesterol and does the relationship differ between black and white men? *Prostate*, 2015;75: 1877-85
406. Fischer S, Simon RM, Howard L, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, **Freedland SJ**, Vidal AC. Do all men with pathologic Gleason 8-10 have poor outcomes? Results from the SEARCH database. *BJU Intl*, in press
407. Feng T, Sun X, Howard LE, Vidal AC, Gaines AR, Moreira DM, Castro-Santamaria R, Andriole GL, **Freedland SJ**. Metformin use and risk of prostate cancer: results from the REDUCE study. *Cancer Prev Res*, 2015;8: 1055-60
408. Feng TS, Vidal AC, and **Freedland SJ**. Should men diagnosed with prostate cancer hit the gym? *Oncology*, 2015;29: 689-90
409. Gaines AR, Vidal AC, and **Freedland SJ**. Vasectomy: potential links to an increased risk of aggressive prostate cancer? *Expert Rev of Anticancer Therapy*, 2015;15: 1123-5
410. Klaassen Z, Howard LE, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, **Freedland SJ**. Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer —results from the SEARCH database. *Cancer Epi*, 2015;39: 1066-70
411. Armstrong AJ, Healy P, Halabi S, Vollmer R, Lark A, Kemeny G, Ware K, and **Freedland SJ**. Evaluation of an epithelial plasticity (EP) biomarker panel in men with localized prostate cancer. *Prost Can Prost Dis*, 2016;19: 40-5
412. Zhu Y, Han CT, Zhang GM, Liu F, Ding Q, Xu JF, Vidal AC, **Freedland SJ**, Ng CF, and Ye DW. Development and external validation of a prostate health index-based nomogram for predicting prostate cancer. *Sci Reports*, 2015;16: 15341

413. Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, **Freedland SJ**. Is a CT a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from SEARCH . *Cancer*, 2016;11: 222-9
414. Cancer Genome Atlas Research Network (**Freedland SJ**, Collaborator). The molecular taxonomy of primary prostate cancer. *Cell*, 2015;163: 1011-25
415. Tay KJ, Gupta RT, **Freedland SJ**, Moul JW, Polascik TJ. Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls. *Expert Review of Anticancer Therapy*, in press
416. McGinley K, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, **Freedland SJ**. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the SEARCH database. *Int J Urol*, in press
417. Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal AC, Castro-Santamaria R, **Freedland SJ**. Does prostate size predict the development of incident lower urinary tract symptoms in men with mild to no current symptoms? Results from REDUCE. *Eur Urol*, in press
418. Zhu Y, Han CT, Zhang GM, Liu F, Ding Q, Xu JF, Vidal AC, **Freedland SJ**, Ng CF, Ye DW. Effect of body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. *Sci Rep*. 2016;6:19034
419. **Freedland SJ**, Howard LE, Hanyok BT, Kadiyala VK, Kuang JY, Whitney CA, Wilks FR, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Aronson WJ, and Moreira DM. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. *BJUI*, in press
420. Moreira DM, Nickel JC, Andriole GL, Castro-Santamaria R, and **Freedland SJ**. Greater extent of prostate inflammation in the negative biopsies is associated with lower risk of prostate cancer: results from REDUCE. *Prost Can Prost Dis*, in press
421. **Freedland SJ**, Choerung V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, Dicker AP, Karnes RJ and Den RB. Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy. *Eur Urol*, in press
422. Allott EH, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, **Freedland SJ**. Racial differences in the association between preoperative serum cholesterol and prostate cancer recurrence: results from the SEARCH database. *Can Epi Biom Prev*, in press
423. Lewis SL, Patel, Song H, **Freedland SJ**, Bynum S, Oh D, Palta M, Yoo D, Oleson J, and Salama JK. Image guided hypofractionated postprostatectomy intensity modulated radiation therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*, 2016;94: 605-11
424. Fischer S, Sun S, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Vidal AC, and **Freedland SJ**. Baseline subject characteristics predictive of compliance with study-

mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE. *Prost Can Prost Dis*, in press

425. Freedland SJ and Den R, Reply to Fossati et al. *Eur Urol*, in press

426. Jamnagerwalla J, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, **Freedland SJ**. The association between phosphodiesterase type-5 inhibitors and prostate cancer: results from the REDUCE study. *J Urol*, in press

Chapters

1. **Freedland SJ** and Belldegrun AS. Renal cell carcinoma-metastatic (N+, M+). In: Gomella LG (ed), *The 5 minute urology consult*, pp. 456-457. Philadelphia: Lippincott Williams & Wilkins, 2000.

2. **Freedland SJ** and Belldegrun AS. Renal cell carcinoma-pediatric. In: Gomella LG (ed), *The 5 minute urology consult*, pp. 458-459. Philadelphia: Lippincott Williams & Wilkins, 2000.

3. **Freedland SJ** and Belldegrun AS. New perspectives in the treatment of prostate cancer. In: Kirk D (ed), *International handbook of prostate cancer: 2nd Ed*. Surrey, England: Euromed Communications Ltd., 2002

4. **Freedland SJ**, Zisman A, and Belldegrun AS. Tumor vaccines. In: Belldegrun AS (ed), *Renal and adrenal tumors-biology and management*, pp 126-134: 1st Ed. Oxford University Press, 2002

5. **Freedland SJ** and Aronson WJ. Obesity and prostate cancer. In: Partin AW (ed), *Prostate Cancer: Principles and Practice: 1st Ed*. Martin Dunitz Ltd, in press

6. Bañez L and **Freedland SJ**. Impact of Host Factors and Co-Morbid Conditions. In: Taneja SS (ed), *Complications Of Urologic Surgery: Diagnosis and Prevention: 4th Ed*. Saunders, in press

7. **Freedland, SJ**. Measurement of prostate specific antigen. In: UpToDate, Rose BD (Ed), *UpToDate*, Waltham, MA, 2007

8. Moreira DM, **Freedland SJ**, Moul JW, and Bañez LL. Systemic treatment of recurrence after local therapies. in: Horwich A. *Systemic Treatments for Prostate Cancer*, 1st edition, Oxford University Press, 2009.

9. Bañez LL, **Freedland SJ**, Moul JW. *Comprehensive Textbook of Genitourinary Oncology 4th Edition*. Vogelzang NJ, *et al.* eds. Chapter 14D: "Recurrence Following Radical Prostatectomy: Definitions and Management" Lippincott Williams & Wilkins, in press

Abstracts

1. **Freedland SJ**, Zadourian Z, Li JH, Borchers HM, Bennett MJ, Gumerlock PH, Larson T, Malone RW, and Erickson KL. Inhibition of prostate tumor cell growth using ribozymes against interleukin-6, Keystone Symposium on Ribozymes, Breckenridge, CO, Jan 1995
2. **Freedland SJ**, Zadourian Z, Bennett MJ, Balasubramaniam RP, Erickson KL, and Malone RW. A model system to assess ribozyme delivery to target cells. J Invest Med 43, 163A, 1995
3. **Freedland SJ**, Zadourian Z, Li JH, Borchers HM, Bennett MJ, Gumerlock PH, Larson T, Malone RW, and Erickson KL. Inhibition of prostate tumor cell growth using ribozymes against interleukin-6. J Invest Med 43, 90A, 1995
4. **Freedland SJ**, Zadourian Z, Li JH, Borchers HM, Bennett MJ, Gumerlock PH, Larson T, Malone RW, Malone J, and Erickson KL. Inhibition of prostate tumor cell growth using ribozymes against interleukin-6. National Student Research Forum, Galveston, TX, 1995
5. **Freedland SJ**, Zadourian Z, Li JH, Borchers HM, Bennett MJ, Gumerlock PH, Larson T, Malone RW, Malone J, and Erickson KL. Inhibition of prostate tumor cell growth using ribozymes against interleukin-6. First Annual Symposium on Cancer Research, UC Davis School of Medicine, 1995
6. **Freedland SJ**, Sutter ME, Naitoh J, Dorey F, Csathy GS, and Aronson WJ. Clinical characteristics and surgical outcome in black and white men with prostate cancer in an equal access medical center. AUA National Meeting, 1999
7. Jalkut M, **Freedland SJ**, Dorey F, and Aronson WJ. Utility of pre-operative and pathological factors to predict surgical outcome in black and white men with prostate cancer in an equal access medical center. AUA National Meeting, 2000
8. **Freedland SJ**, Dorey F, and Aronson WJ. Multivariate analysis of race and adverse pathological findings following radical prostatectomy. AUA Western Section Meeting, 2000
9. **Freedland SJ**, Tso CL, Pantuck AJ, Caliliw R, Nguyen D, Zisman A, Matherly J, Beldegrun AS. Cellular and Molecular Characterization of the Heterogeneity of Hormone Refractory Prostate Cancer Using a Unique Single Cell Derived and GFP expressing Clonal Tumor Model. AACR National Meeting, 2001
10. Pantuck AJ, **Freedland SJ**, Zisman A, Matherly J, Tso CL, Beldegrun AS. A Fluorescence Labeled, Single Cell-Derived, Metastatic Tumor Model for Hormone Refractory Prostate Cancer. AACR National Meeting, 2001
11. **Freedland SJ**, Blanco-Yarosh M, Rajfer J, Sun JC, Hale SJ, Smith RB, Elashoff D, and Gritsch HA. Cost-efficient open donor nephrectomy using a clinical care pathway. AUA National Meeting, 2001

12. **Freedland SJ**, Blanco-Yarosh M, Litwin MS, Rajfer J, Sun JC, Hale SJ, Smith RB, Elashoff D, and Gritsch HA. Improved open donor nephrectomy using a clinical care pathway and ketorolac for post-operative pain. AUA National Meeting, 2001
13. **Freedland SJ**, Csathy GS, Dorey F, and Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive than PSA or Gleason score for predicting biochemical failure or adverse pathology following radical prostatectomy. AUA Western Section Meeting, 2001
14. **Freedland SJ**, Liu AY, Pantuck AJ, Zisman A, Nguyen D, Tso CL, Paik SH, and Belldregun AS. In vivo modeling of prostate cancer progression using a novel fluorescent-labeled, clonal tumor system. AUA Western Section Meeting, 2001
15. **Freedland SJ**, Blanco-Yarosh M, Sun JC, Hale SJ, Elashoff DA, Litwin MS, Smith RB, Rajfer J, and Gritsch HA. Impact of ketorolac on patients undergoing unilateral nephrectomy: safety and efficacy. AUA Western Section Meeting, 2001
16. **Freedland SJ**, Liu AY, Pantuck AJ, Zisman A, Nguyen D, Tso CL, Paik SH, and Belldregun AS. In vivo modeling of prostate cancer progression using a novel fluorescent-labeled, clonal tumor system. AUA National Meeting, 2002
17. Terris MK, **Freedland SJ**, Amling CL, Dorey F, Kane CJ, Presti JC Jr., and Aronson WJ. Race as an outcome predictor following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. AUA National Meeting, 2002
18. **Freedland SJ**, Kane CJ, Presti JC Jr., Terris MK, Amling CL, Dorey F, and Aronson WJ. Pre-operative PSA density improves risk stratification for biochemical recurrence following radical prostatectomy: Results from the SEARCH database. AUA Western Section Meeting, 2002
19. **Freedland SJ**, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, and Aronson WJ. Preoperative p27 status is an independent predictor of PSA failure following radical prostatectomy. AUA Western Section Meeting, 2002
20. **Freedland SJ**, Seligson DS, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, and Belldregun AS. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. AUA Western Section Meeting, 2002
21. **Freedland SJ**, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, and Belldregun AS. Heterogeneity of molecular targets on clonal cancer clones derived from a novel hormone-refractory prostate cancer tumor system. AUA Western Section Meeting, 2002
22. **Freedland SJ**, Amling CL, Aronson WJ, Dorey F, Kane CJ, Presti JC Jr., and Terris MK. Time trends in biochemical recurrence following radical prostatectomy: Results of the SEARCH Database. AUA Western Section Meeting, 2002

23. **Freedland SJ**, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, and Amling CL. The role of biopsy laterality for T1c and T2 prostate cancer: results from the SEARCH database. AUA Western Section Meeting, 2002
24. **Freedland SJ**, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, and Amling CL. The role of biopsy laterality for T1c and T2 prostate cancer: results from the SEARCH database. Society of Urological Oncology, 2002
25. **Freedland SJ**, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, and Aronson WJ. Predicting biochemical recurrence following radical prostatectomy for patients with organ-confined disease using p27 expression. Society of Urological Oncology, 2002
26. **Freedland SJ**, Aronson WJ, Presti JC Jr., Kane CJ, Terris MK, Elashoff D, and Amling CL. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH Database. Society of Urological Oncology, 2002
27. **Freedland SJ**, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, and Aronson WJ. Preoperative p27 status is an independent predictor of PSA failure following radical prostatectomy. AUA National Meeting, 2003
28. Ngo TH, Barnard RJ, Cohen P, **Freedland SJ**, Tran C, deGregorio F, Elshimali YI, Heber D, and Aronson WJ. Effect of isocaloric low-fat diet on human LAPC-4 prostate xenografts in SCID mice and the IGF axis. AUA National Meeting, 2003
29. **Freedland SJ**, Aronson WJ, Presti JC Jr., Kane CJ, Terris MK, Elashoff D, and Amling CL. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH Database. AUA National Meeting, 2003
30. **Freedland SJ**, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, and Amling CL. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. AUA National Meeting, 2003
31. **Freedland SJ**, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent of prostate needle biopsy cores with cancer is a significant independent predictor of PSA recurrence following radical prostatectomy: Results from the SEARCH Database. AUA National Meeting, 2003
32. Perry KT, **Freedland SJ**, Hu J, Phelan M, Kristo B, Gritsch AH, Rajfer J, and Schulam PG. Quality of life, pain, and return to normal activities following laparoscopic donor nephrectomy vs. open mini-incision donor nephrectomy. AUA National Meeting, 2003
33. **Freedland SJ**, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? AUA Western Section Meeting, 2003
34. **Freedland SJ**, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Aronson, WJ. Pre-operative model for predicting PSA recurrence after radical prostatectomy

using percent of biopsy tissue with cancer, biopsy Gleason grade, and serum PSA. AUA Western Section Meeting, 2003

35. **Freedland SJ**, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. AUA Western Section Meeting, 2003

36. **Freedland SJ**, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. Society of Urological Oncology, 2003

37. **Freedland SJ**, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Aronson, WJ. Pre-operative model for predicting PSA recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade, and serum PSA. Society of Urological Oncology, 2003

38. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, deKernion JB, and **Freedland SJ**. Predictors of metastatic disease among men with biochemical failure following radical prostatectomy. Society of Urological Oncology, 2003

39. **Freedland SJ**, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. AUA Southeastern Section Meeting, 2004

40. **Freedland SJ**, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? AUA Southeastern Section Meeting, 2004

41. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, deKernion JB, and **Freedland SJ**. Predictors of metastatic disease among men with biochemical failure following radical prostatectomy. AUA National Meeting, 2004

42. **Freedland SJ**, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. AUA National Meeting, 2004

43. **Freedland SJ**, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? AUA National Meeting, 2004

44. **Freedland SJ**, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr., Trock B, and Amling CL. Men with normal pre-operative serum PSA values have better biochemical outcomes following radical prostatectomy. AUA National Meeting, 2004

45. **Freedland SJ**, Mangold LA, Epstein JI, and Partin AW. Biopsy indication - a predictor of pathological stage among men with pre-operative serum PSA levels ≤ 4.0 ng/mL and T1c disease. AUA National Meeting, 2004

46. **Freedland SJ**, Partin AW, Epstein JI, and Walsh PC. No difference in PSA failure rates following radical prostatectomy between men with pT2a and pT2b tumors. AUA National Meeting, 2004

47. **Freedland SJ**, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent of prostate needle biopsy cores with cancer from the most involved side of the biopsy is a better predictor of PSA recurrence following radical prostatectomy than the total percent of cores with cancer. AUA National Meeting, 2004

48. Ngo TH, Barnard RJ, Anton T, Tran C, Elashoff D, Heber D, **Freedland SJ**, and Aronson WJ. Effect of isocaloric low-fat diet on LAPC-4 prostate tumor progression to androgen-independence in severe combined immunodeficient mice. *Journal of Investigative Medicine* 54(1), 2004

49. **Freedland SJ**, Luo J, DeMarzo AM, Dunn T, Fedor H, and Isaacs WB. Gene expression differences between prostate cancers from obese and normal weight men. AACR National Meeting, 2004

50. **Freedland SJ**, Kane CJ, Terris MK, Presti JC Jr. , Trock B, and Amling CL. Men with normal pre-operative serum PSA values have better biochemical outcomes following radical prostatectomy. AUA Western Section Meeting, 2004

51. **Freedland SJ**, Presti JC Jr. , Amling CL, Kane CJ, Trock B, and Terris MK. Obesity and biochemical outcome following radical prostatectomy for organ-confined disease with negative surgical margins. AUA Western Section Meeting, 2004

52. **Freedland SJ**, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr. , and Terris MK. Adult height predicts biochemical progression following radical prostatectomy among black men but not white men. AUA Western Section Meeting, 2004

53. **Freedland SJ**, Isaacs WB, Platz E, Terris M, Amling CL, Presti JC Jr. , and Kane CJ. Prostate size is inversely correlated with risk of high-grade, advanced cancer, and biochemical progression following radical prostatectomy. AUA Western Section Meeting, 2004

54. **Freedland SJ**, Isaacs WB, Platz E, Presti JC Jr., Amling CL, Kane CJ, and Terris MK. Race, anthropomorphic measurements and prostate size. AUA Western Section Meeting, 2004

55. Aronson WJ, Kobayashi N, Lueng P, Hong J, Barnard RJ, **Freedland SJ**, Elashoff D, Heber D, Henning S, Varr B, Said J, Giri D, Reddy S, Bagga D, Glaspy J, and Cohen P. Inhibitory effect of dietary fish oil (omega-3 fatty acids) on human prostate cancer progression in severe-combined immunodeficient mice. AUA Western Section Meeting, 2004

56. Aronson WJ, **Freedland SJ**, Conde F, Kobayashi N, Cohen P, Huang D, Ngo T, Lueng P, Bowerman S, Hong J, Varr B, deMiranda P, Elashoff D, Glaspy J, Henning S, Heber D, and Barnard RJ. Growth inhibitory effect of a low-fat diet on prostate cancer in vitro: results of a prospective randomized intervention trial in men with prostate cancer. AUA Western Section Meeting, 2004

57. **Freedland SJ**, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Terris MK. Characteristics of Asian American Veterans Undergoing Radical Prostatectomy: Results from the SEARCH Database. International Cooperative Study of Diagnostic Ultrasound and Prostate Cancer. 2004, Tokyo, Japan
58. **Freedland SJ**, Isaacs WB, Mangold L, Yiu SK, Grubb KA, Partin AW, Epstein JI, Walsh PC, Platz EA. Stronger association between obesity and biochemical progression following radical prostatectomy among men treated in the last 10 years. Prostate Cancer Foundation, 2004
59. **Freedland SJ**, Luo J, DeMarzo AM, Dunn T, Fedor H, Mohan I, Darshan M, and Isaacs WB. Gene expression differences between prostate cancers from obese and normal weight men. Prostate Cancer Foundation, 2004
60. **Freedland SJ**, Luo J, DeMarzo AM, Dunn T, Fedor H, Mohan I, Darshan M, and Isaacs WB. Gene expression differences between prostate cancers from obese and normal weight men. Society of Urological Oncology, 2004
61. Kobayashi N, Lueng P, Hong J, Barnard RJ, **Freedland SJ**, Elashoff D, Heber D, Henning S, Varr B, Said J, Giri D, Reddy S, Bagga D, Glaspy J, and Aronson WJ,. Inhibitory effect of dietary fish oil (omega-3 fatty acids) on human prostate cancer progression in severe-combined immunodeficient mice. AUA National Meeting, 2005
62. Aronson WJ, **Freedland SJ**, Conde F, Kobayashi N, Cohen P, Huang D, Ngo T, Lueng P, Bowerman S, Hong J, Varr B, deMiranda P, Elashoff D, Glaspy J, Henning S, Heber D, and Barnard RJ. Growth inhibitory effect of a low-fat diet on prostate cancer in vitro: results of a prospective randomized intervention trial in men with prostate cancer. AUA National Meeting, 2005
63. **Freedland SJ**, Haffner MC, Landis PK, Saigal CS, and Carter HB. Obesity does not negatively impact on health related quality of life outcomes after anatomic retropubic radical prostatectomy. AUA National Meeting, 2005
64. **Freedland SJ**, Haffner MC, Landis PK, Saigal CS, and Carter HB. Health related quality of life outcomes after anatomic retropubic radical prostatectomy: impact of neurovascular bundle preservation. AUA National Meeting, 2005
65. Kane CJ, Aronson WJ, Terris MK, Amling CL, Presti JC, and **Freedland SJ**. High-risk patients undergoing radical prostatectomy today are less high-risk than in the past. AUA National Meeting, 2005
66. **Freedland SJ**, Isaacs WB, Platz E, Terris M, Aronson WJ, Amling CL, Presti JC Jr. , and Kane CJ. Prostate size is inversely correlated with risk of high-grade, advanced cancer, and biochemical progression following radical prostatectomy. AUA National Meeting, 2005
67. **Freedland SJ**, Terris MK, Platz EA, and Presti JC. Body mass index as a predictor of prostate cancer: development vs. detection on biopsy. AUA National Meeting, 2005

68. **Freedland SJ**, Luo J, DeMarzo AM, Dunn T, Fedor H, Darshan M, Mohan I, and Isaacs WB. Gene expression differences between prostate cancers from obese and normal weight men. AUA National Meeting, 2005
69. **Freedland SJ**, Isaacs WB, Mangold L, Yiu SK, Grubb KA, Partin AW, Epstein JI, Walsh PC, Platz EA. Stronger association between obesity and biochemical progression following radical prostatectomy among men treated in the last 10 years. AUA National Meeting, 2005
70. Nielsen ME, Han M, Walsh PC, Partin AW, and **Freedland SJ**. Body mass index and outcomes in African-American and Caucasian men following radical prostatectomy for clinically localized prostate cancer. AUA National Meeting, 2005
71. **Freedland SJ**, Humphreys EB, Mangold LA, Eisenberger M, Walsh PC, and Partin AW. Who dies from prostate cancer after radical prostatectomy: influence of post-operative prostate specific antigen doubling time, pathological Gleason sum, and time from surgery to biochemical recurrence. AUA National Meeting, 2005
72. **Freedland SJ**, Sokoll LJ, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Epstein JI, and Partin AW. Serum leptin does not predict pathological stage among men treated with radical prostatectomy. AUA National Meeting, 2005
73. Nielsen ME, **Freedland SJ**, Zderic SA, Jarow JP. Insight on the pathogenesis of varicoceles: relationship of varicocele with BMI. AUA National Meeting, 2005
74. Bastian PJ, Gonzalgo ML, **Freedland SJ**, Mangold LA, and Partin AW. Clinical and pathological outcome after radical prostatectomy for prostate cancer with a preoperative Gleason score 8 to 10. AUA National Meeting, 2005
75. **Freedland SJ**, Luo J, DeMarzo AM, Dunn T, Fedor H, Darshan M, Mohan I, and Isaacs WB. Gene expression differences between prostate cancers from obese and normal weight men. AACR National Meeting, 2005
76. **Freedland SJ**, Humphreys EB, Mangold LA, Eisenberger M, Walsh PC, and Partin AW. Predicting prostate cancer specific mortality following biochemical recurrence after radical prostatectomy. ASCO National Meeting, 2005
77. **Freedland SJ**, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr., and Terris MK. Delay in receiving radical prostatectomy and risk of biochemical progression among men with low-risk prostate cancer. Society of Urologic Oncology, 2005
78. **Freedland SJ**, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr., and Terris MK. Delay in receiving radical prostatectomy and risk of biochemical progression among men with low-risk prostate cancer. ASCO Prostate Cancer Symposium, 2006

79. **Freedland SJ**, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, Kane CJ, and Terris MK. Obesity, serum PSA, and prostate size: implications for prostate cancer detection. ASCO Prostate Cancer Symposium, 2006

80. Cullen J, **Freedland S**, Chen Y, Chang Z, Zhao J, Dobi A, and McLeod D. Using PSA doubling time (DT) to predict overall survival for prostate cancer patients who experience PSA failure after surgery. ASCO Prostate Cancer Symposium, 2006

81. **Freedland SJ**, Wang A, Mavropoulos J, Darshan M, Demark-Wahnefried W, Aronson WJ, and Isaacs WB. A low-carbohydrate ketogenic diet significantly delays prostate cancer growth and prolongs survival in a mouse xenograft model. AACR National Meeting, 2006

82. **Freedland SJ**, Humphreys EB, Mangold LA, Eisenberger M, and Partin AW. Time to PSA recurrence after radical prostatectomy and risk of prostate cancer specific mortality. AUA National Meeting, 2006

83. **Freedland SJ**, Kane CJ, Amling CL, Aronson WJ, Terris MT, and Presti JC Jr. Undergrading and overgrading of prostate needle biopsies: risk factors and clinical implications. AUA National Meeting, 2006

84. Cooperberg MR, **Freedland SJ**, Pasta DJ, Elkin EP, Presti, JC, Jr., Amling CL, Terris MK, Aronson WA, Kane CJ, and Carroll PR. Multi-institutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence following radical prostatectomy. AUA National Meeting, 2006

85. Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, and **Freedland SJ**. Pathologic outcomes and PSA progression in men with T1c prostate cancer undergoing radical prostatectomy with low PSA (2.6-4.0 ng/ml) versus slightly elevated PSA (4.1-6.0 mg/ml). AUA National Meeting, 2006

86. **Freedland SJ**, Darshan M, Wang A, Luo J, DeMarzo AM, Dunn T, Fedor H, Mohan I, Mavropoulos J, Demark-Wahnefried W, Aronson W, and Isaacs WB. Gene expression profiling of prostate cancers from obese men identified HMGCS2 as a novel biomarker of aggressive prostate cancer and as a potential therapeutic target. AUA National Meeting, 2006

87. **Freedland SJ**, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, Kane CJ, and Terris MK. Obesity, serum PSA, and prostate size: implications for prostate cancer detection. AUA National Meeting, 2006

88. Shah S, **Freedland SJ**, Presti JC Jr., Aronson WJ, Amling CL, Kane CJ, and Terris MK. Agent Orange exposure and risk of advanced disease and biochemical progression after radical prostatectomy: results from the SEARCH database. AUA National Meeting, 2006

89. Scales CD Jr, Amling CL, Kane CJ, Presti JC Jr, Terris MK, Aronson WJ, **Freedland, SJ** Can unilateral prostate cancer be reliably predicted based upon biopsy features? AUA National Meeting, 2006

90. Bastian PJ, Gonzalgo ML, Mangold LA, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC, Epstein JI, Partin AW, **Freedland SJ**. Pathological and biochemical outcomes after radical prostatectomy for men with a biopsy Gleason score of 8 to 10. AUA National Meeting, 2006
91. Shah S, **Freedland SJ**, Aronson W, Terris M. Adverse clinical characteristics in prostate cancer and exposure to Agent Orange: is there a link? AUA Southeastern Section, 2006
92. Terris MK, **Freedland SJ**, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, and Kane CJ. Obesity, serum PSA, and prostate size: implications for prostate cancer detection. AUA Southeastern Section, 2006
93. Hamilton RJ, Buschemeyer WC III, Terris MK, Aronson WJ, Kane CJ, Presti JC Jr, Amling CJ, and **Freedland SJ**. Significance of the apical margin in radical prostatectomy: results from the SEARCH database. ASCO Prostate Cancer Symposium, 2007
94. Wong YN, **Freedland SJ**, Hudes G, Schwartz JS, Montagnet C, and Armstrong K. Role of androgen deprivation therapy (ADT) for node-positive prostate cancer. ASCO Prostate Cancer Symposium, 2007
95. Bañez LL, Hamilton RJ, Vollmer RT, Moul JW, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and **Freedland SJ**. Can hemodilution explain the lower PSA concentrations among obese men? ASCO Prostate Cancer Symposium, 2007
96. Buschemeyer WC III, Hamilton RJ, Amling CL, Kane CJ, Terris MK, Aronson WJ, Presti JC Jr, and **Freedland SJ**. Is a positive bladder neck margin truly a T4 lesion in the PSA era? Results from the SEARCH database. ASCO Prostate Cancer Symposium, 2007
97. Hamilton RJ, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and **Freedland SJ**. African American race, risk of biochemical recurrence, and PSADT after radical prostatectomy. ASCO Prostate Cancer Symposium, 2007
98. Fitzsimons NJ, Sun LL, Dahm P, Moul JW, Madden J, Gan TJ, and **Freedland SJ**. A single-institution comparison between radical perineal and radical retropubic prostatectomy on peri-operative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. ASCO Prostate Cancer Symposium, 2007
99. **Freedland SJ**, Hotaling JM, Fitzsimons NJ, Pesti JC Jr, Kane CJ, Terris MK, Aronson WJ, and Amling CL. PSA in the new millennium: still a good predictor of prostate cancer prognosis and treatment outcomes? ASCO Prostate Cancer Symposium, 2007
100. Kang DE, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, and **Freedland SJ**. Risk stratification of men with Gleason 7-10 tumors by primary and secondary Gleason score: results from the SEARCH database. ASCO Prostate Cancer Symposium, 2007

101. Buschemeyer WC III, Hamilton RJ, Terris MK, Aronson WJ, Kane CJ, Presti JC Jr, Amling CJ, and **Freedland SJ**. Significance of the apical margin in radical prostatectomy: results from the SEARCH database. AUA Southeastern Section, 2007

102. Buschemeyer WC III, Hamilton RJ, Amling CL, Kane CJ, Terris MK, Aronson WJ, Presti JC Jr, and **Freedland SJ**. Is a positive bladder neck margin truly a T4 lesion in the PSA era? Results from the SEARCH database. AUA Southeastern Section, 2007

103. Fitzsimons NJ, Sun LL, Dahm P, Moul JW, Madden J, Gan TJ, and **Freedland SJ**. A single-institution comparison between radical perineal and radical retropubic prostatectomy on peri-operative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. AUA Southeastern Section, 2007

104. Kang DE, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, and **Freedland SJ**. Risk stratification of men with Gleason 7-10 tumors by primary and secondary Gleason score: results from the SEARCH database. AUA Southeastern Section, 2007

105. Scales CD Jr, Amling CL, Kane CJ, Presti JC Jr, Terris MK, Aronson WJ, **Freedland, SJ** Can unilateral prostate cancer be reliably predicted based upon biopsy features? AUA Southeastern Section, 2007

106. Hamilton RJ, Buschemeyer WC III, Terris MK, Aronson WJ, Kane CJ, Presti JC Jr, Amling CJ, and **Freedland SJ**. Significance of the apical margin in radical prostatectomy: results from the SEARCH database. AUA National Meeting, 2007

107. Hamilton RJ, Goldberg KC, Platz EA, **Freedland SJ**. The influence of statin medications on prostate specific antigen levels in healthy men. AUA National Meeting, 2007

108. Bañez LL, Hamilton RJ, Vollmer RT, Moul JW, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and **Freedland SJ**. Can hemodilution explain the lower PSA concentrations among obese men? AUA National Meeting, 2007

109. Buschemeyer WC III, Mavropoulos J, Pizzo S, Demark-Wahnenfried W, Westman E, and **Freedland SJ**. Effect of diet on LNCaP prostate cancer growth and survival in SCID mice. AUA National Meeting, 2007

110. Buschemeyer WC III, Hamilton RJ, Amling CL, Kane CJ, Terris MK, Aronson WJ, Presti JC Jr, and **Freedland SJ**. Is a positive bladder neck margin truly a T4 lesion in the PSA era? Results from the SEARCH database. AUA National Meeting, 2007

111. Shah SR, **Freedland SJ**, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, and Terris MK. Agent Orange exposure among black men is a stronger predictor of PSA recurrence and rapid post-recurrence PSADT than among white men. AUA National Meeting, 2007

112. King KR, **Freedland SJ**, Terris MK, Aronson WJ, Kane CJ, Amling CL, and Presti JC Jr. The optimal timing, cutoff and method of calculation of preoperative PSA velocity to predict relapse after prostatectomy: a report from SEARCH database. AUA National Meeting, 2007

113. Nelles JL, **Freedland SJ**, Presti JC Jr, Terris MK, Aronson WJ, Amling CL, and Kane CJ. Nerve sparing does not increase the risk of biochemical recurrence: results from the SEARCH database. AUA National Meeting, 2007

114. Hamilton RJ, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and **Freedland SJ**. African American race, risk of biochemical recurrence, and PSADT after radical prostatectomy. AUA National Meeting, 2007

115. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki B, Thompson I, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, and **Freedland SJ**. Are the Partin tables accurate for African-American men in the United States? AUA National Meeting, 2007

116. **Freedland SJ**, Hamilton RJ, Aronson WJ, Terris MK, Pesti JC Jr, Amling CL, and Kane CJ. Obesity, risk of biochemical recurrence, and PSADT after radical prostatectomy. AUA National Meeting, 2007

117. Gross M, Nepomuceno E, Luthringer D, Vollmer RT, Burchette J Jr, and **Freedland SJ**. Androgen receptor and estrogen receptor beta associates with Gleason score, but not obesity, in prostate cancer. AUA National Meeting, 2007

118. **Freedland SJ**, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, and Partin AW. Death in patients with recurrent prostate cancer after radical prostatectomy: PSADT subgroups and their associated contributions to all-cause mortality. AUA National Meeting, 2007

119. **Freedland SJ**, Partin AW, Humphreys EB, Mangold LA, and Walsh PC. Radical prostatectomy for clinical stage T3 disease. AUA National Meeting, 2007

120. **Freedland SJ**, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Pizzo S, Aronson WJ, Cohen P, and Isaacs WB. A no-carbohydrate diet significantly delays prostate cancer growth in an animal model. AUA National Meeting, 2007

121. Teeter AE, Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ, and **Freedland SJ**. What are the factors associated with a short PSA doubling time? – a report from the SEARCH database group. Society of Urologic Oncology, 2007

122. Klink JC, Bañez LL, Powell IP, Aronson WJ, Terris MK, Kane CJ, Amling CL and **Freedland SJ**. T1C Disease in black men: a more aggressive disease? Results from the SEARCH database group. Society of Urologic Oncology, 2007

123. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti Jr. JC, Amling CL, Kane CJ, and **Freedland SJ**. Obesity as a predictor of adverse outcome across black and white race. Results from the SEARCH database group. Society of Urologic Oncology, 2007

124. Bañez LL, Sun L, Aronson WJ, Terris MK, Presti JC Jr., Kane CJ, Amling CL, Moul JW, and **Freedland SJ**. Is PSA a poor predictor of adverse pathology and biochemical failure following radical prostatectomy in obese men? Society of Urologic Oncology, 2007

125. Bañez LL, Sun L, Aronson WJ, Terris MK, Presti JC Jr., Kane CJ, Amling CL, Moul JW, and **Freedland SJ**. Is PSA a poor predictor of adverse pathology and biochemical failure following radical prostatectomy in obese men? ASCO GU Cancers, 2008
126. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti Jr. JC, Amling CL, Kane CJ, and **Freedland SJ**. Obesity as a predictor of adverse outcome across black and white race. Results from the SEARCH database group. ASCO GU Cancers, 2008
127. Teeter AE, Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ, and **Freedland SJ**. What are the factors associated with a short PSA doubling time? – a report from the SEARCH database group. ASCO GU Cancers, 2008
128. Trock BJ, Han M, **Freedland SJ**, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival in men with biochemical recurrence after radical prostatectomy: impact of salvage radiation therapy vs. observation. ASCO GU Cancers, 2008
129. Jayachandran J, Bañez LL, Levy De, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, and **Freedland SJ**. Risk stratification for biochemical recurrence among men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. ASCO GU Cancers, 2008
130. Scales Jr CD, Terris MK, Aronson WJ, Presti JC Jr., Kane CJ, Amling CL, Krupski TL, and **Freedland SJ**. Does practice reflect the evidence? Lymph node dissection with radical prostatectomy; results from the SEARCH Database. AUA Annual Meeting, 2008
131. Turley RS, Hamilton RJ, Terris MK, Kane, CJ, Aronson W, Presti JC Jr., Amling CL and **Freedland SJ**. Small TRUS volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH Database. AUA Annual Meeting, 2008
132. Teeter AE, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ and **Freedland SJ**. Does early PSADT, calculated starting at the first detectable PSA after radical prostatectomy correlate with standard PSADT? Report from the SEARCH database group. AUA Annual Meeting, 2008
133. Bañez LL, Hamilton RJ, Aronson WJ, Terris MK, Presti JC Jr., Kane CJ, Amling CL and **Freedland SJ**. Higher cholesterol increases the risk of biochemical failure after radical prostatectomy: results from the search database group. AUA Annual Meeting, 2008
134. Teeter AE, Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ and **Freedland SJ**. What are the factors associated with a short PSA doubling time? Report from the SEARCH database group. AUA Annual Meeting, 2008
135. Fitzsimons NJ, Sun LL, Moul JW, Madden J and **Freedland SJ**. Obese men have larger and higher-grade tumors: An analysis of the Duke Prostate center database. AUA Annual Meeting, 2008

136. Lin DW, Terris MK, Aronson WJ, Presti JC Jr., Kane CJ, Amling CL and **Freedland SJ**. Outcome among men with Pathological Gleason sum 8-10 prostate cancer at the time of radical prostatectomy: results from the SEARCH Database. AUA Annual Meeting, 2008
137. **Freedland SJ**, Sun L and Moul JW. Small prostate size predicts biochemical progression after radical prostatectomy. AUA Annual Meeting, 2008
138. Schroeck FR, Sun L, Levy D, Bryan KA, **Freedland SJ**, Jayachandran J, Price M, Williams R and Moul JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. AUA Annual Meeting, 2008
139. Buschemeyer III C, Tewari A, Hsu D, Mavropoulos J, Rokhfeld D, Johnson T, Pizzo S, Febbo P and **Freedland, SJ**. Elimination of dietary carbohydrate extends survival of mice bearing LNCaP xenografts. AUA Annual Meeting, 2008
140. Roberts WB, Dunn TA, Ahaghotu CA, Kittles R, **Freedland SJ**, Isaacs W and Jun L. Differential gene expression in human prostate cancer based on ethnic or geographic origin. AUA Annual Meeting, 2008
141. Jayachandran J, Bañez LL, Levy DL, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ and **Freedland SJ**. Risk stratification among men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. AUA Annual Meeting, 2008
142. Trock BJ, Han M, **Freedland SJ**, Humphreys EB, DeWeese TL, Partin AW and Walsh PC. Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy. AUA Annual Meeting, 2008
143. Scales CD Jr., Curtis LH, Schulman KA, **Freedland SJ** and Krupski TL. Utilization of lymph node dissection with radical prostatectomy in the United States. AUA Annual Meeting, 2008
144. Kane CJ, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ, Presti, JC Jr., Amling CL and **Freedland SJ**. PSA Velocity (PSAV) to cancer-specific PSA (PSA(PCa)) ratio increases with higher Gleason score: results from the SEARCH Database AUA Annual Meeting, 2008
145. **Freedland SJ**, Sun L, Neville TB, Kaminski DA, Falvello VB and Moul JW. Dynamic screening for prostate cancer improves AUCs relative to static screening using a single PSA Threshold: results from the Duke Prostate center. AUA Annual Meeting, 2008
146. Bañez LL, Aronson WJ, Wen JW, Wuerstle M, Shah A, Lai D, Moalej B, Atala C, and **Freedland SJ**. Is PSA a poor predictor of prostate cancer in obese men? AUA Annual Meeting, 2008
147. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling, CL, Kane CK, Sun L, Moul JW and **Freedland SJ**. Obesity as a predictor of adverse outcome across black

and white race: results from the SEARCH and Duke Prostate center databases. AUA Annual Meeting, 2008

148. Kane CJ, Terris MK, Aronson WJ, Presti JC Jr., Amling CL and **Freedland SJ**. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH Database. AUA Annual Meeting, 2008

149. Klink JC, Bañez LL, Powell IJ, Aronson WJ, Terris MK, Kane CJ, Amling, CL and **Freedland SJ**. T1C disease in black men: a more aggressive disease: results from the SEARCH database. AUA Annual Meeting, 2008

150. **Freedland SJ**, Terris MK, Aronson WJ, Presti, JC Jr., Amling CL and Kane CJ. Over the last 15+ years, the percentage of men undergoing radical prostatectomy who are candidates for active surveillance has not changed: results from the SEARCH Database. AUA Annual Meeting, 2008

151. **Freedland SJ**, Moul JW, Sun L, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ, Presti, JC Jr., Amling CL, Kane CJ. Dynamic screening detects prostate cancer earlier and would lead to improved cancer control: results from the Duke Prostate center and the SEARCH database. AUA Annual Meeting, 2008

152. Hamilton RJ, Platz EA, Goldberg KC and **Freedland SJ**. The association between cholesterol and PSA. AUA Annual Meeting, 2008

153. Bañez LL, Sun L, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ, Moul JW and **Freedland SJ**. Is PSA a poor predictor of adverse pathology and biochemical failure following radical prostatectomy in obese men? AUA Annual Meeting, 2008

154. Potter MQ, **Freedland SJ**, Poulton S, Dewhirst M, and Jones LW. Effects of exercise training on growth of LAPC-4 prostate cancer xenografts. AACR Annual Meeting, 2008

155. Buschemeyer WC, Klink J, Mavropoulos M, Demark-Wahnefried W, Johnson T, Poulton S, Hursting S, and **Freedland SJ**. Effect of intermittent caloric restriction on prostate cancer growth and survival in mice. AACR Annual Meeting, 2008

156. Klink JC, Poulton S, Pizzo SV, and **Freedland SJ**. Resveratrol alters prostate cancer xenograft growth. AACR Annual Meeting, 2008

157. Antonelli J, Jones L, Poulton S, Phillips T, Dewhirst M and **Freedland SJ**. Behavioral and Social Science in Cancer Prevention and Research. AACR Annual Meeting, 2009

158. Hartmann A, Bañez L, Sun L, van Leenders G, Wheeler T, Bangma C, **Freedland SJ**, Ittmann M, Lark A, Madden J, Weiss G and Castanos-Velz E. Clinical validation of PITX2 methylation as predictor of higher risk of PSA recurrence in post-radical prostatectomy prostate cancer patients. AACR Annual Meeting, 2009

159. Lloyd J, Antonelli J, Thomas J, Phillips T, Poulton S, Pizzo S and **Freedland SJ**. No-carbohydrate ketogenic dietary interventions plus castration and prostate cancer: Can eliminating carbohydrates enhance survival? AACR Annual Meeting, 2009
160. Thomas J, Poulton S, Phillips T, Dewhirst M and **Freedland SJ**. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. AACR Annual Meeting, 2009
161. **Freedland SJ**, Mavropoulos J, Buschemeyer W C, Tewari A, Rokhfeld D, Pollak M, Zhao Y, Febbo P, Cohen P, Hwang D, Devi G, Demark-Wahnefried D, Westman E, Peterson B and Pizzo S. A no carbohydrate diet significantly prolongs survival in prostate cancer xenograft model via IGF-1 and global gene expression changes. AUA Annual Meeting, 2009
162. Antonelli J, Jones L, Poulton S, Phillips T, Dewhirst M and **Freedland SJ**. Effects of exercise on prostate cancer growth in a mouse model. AUA Annual Meeting, 2009
163. Lloyd J, **Freedland SJ**, Antonelli J, Poulton S and Phillips T. No-carbohydrate ketogenic dietary interventions on prostate cancer: Can eliminating carbohydrates enhance survival? AUA Annual Meeting, 2009
164. Thomas J, Poulton S, Phillips T, Lloyd J, Antonelli J and **Freedland SJ**. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. AUA Annual Meeting, 2009
165. Schroeck F, Kattan M, Moul J, Aronson W, Presti Jr. J, Terris M, Kane C, Amling C, Sun L and **Freedland SJ**. Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy (RP). AUA Annual Meeting, 2009
166. Thomas J, Jayachandran J, Bañez L, Sun L, Madden J, Vollmer R, Lark A, Gerber L, Moul J and **Freedland SJ**. Does pathological Gleason score re-review by a modern pathologist improve risk stratification relative to historical Gleason score? AUA Annual Meeting, 2009
167. Bañez L, Jayachandran J, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and **Freedland SJ**. Association between statins, obesity and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. AUA Annual Meeting, 2009
168. Jayachandran J, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and **Freedland SJ**. Diabetes and outcomes after radical prostatectomy- are results affected by obesity and race? Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. AUA Annual Meeting, 2009
169. Teeter A, Presti Jr. J, Aronson W, Terris M, Kane C, Amling C and **Freedland SJ**. Does PSADT after radical prostatectomy predict overall survival?—A report from the SEARCH Database Group. AUA Annual Meeting, 2009
170. Klink J, Poulton S, Antonelli J, Potter M, Jayachandran J, Tewari A, Febbo P, Pizzo S and **Freedland SJ**. Resveratrol alters prostate cancer xenograft growth. AUA Annual Meeting, 2009

171. Moreira D, Bañez L, Presti Jr. J, Aronson W, Terris M and **Freedland SJ**. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: Results from the SEARCH Database. AUA Annual Meeting, 2009
172. Jayachandran J, Schroeck F, Sun L, Gerber L, Moreira D, Moul J and **Freedland SJ**. The Shared Equal Access Regional Cancer Hospital (SEARCH) Nomogram for risk stratification in intermediate risk group of men with prostate cancer: Validation in the Duke Prostate Center (DPC) Database. AUA Annual Meeting, 2009
173. Moreira D, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and **Freedland SJ**. Natural history of persistently elevated PSA after radical prostatectomy: Results from the SEARCH Database. AUA Annual Meeting, 2009
174. Moreira D, Jayachandran J, Bañez L, Kane C, Amling C, Stephenson A and **Freedland SJ**. Validation of Stephenson nomogram to predict PSA progression following salvage radiotherapy after radical prostatectomy: Results from the SEARCH Database. AUA Annual Meeting, 2009
175. Bañez L, Moreira D, Krupski T, Aronson W, Presti Jr. J, Terris M, Amling C, Kane C and **Freedland SJ**. Predictors of castration resistant Prostate Cancer in men undergoing salvage androgen deprivation therapy- Results from the SEARCH Database. AUA Annual Meeting, 2009
176. Trock B, Han M, **Freedland SJ**, Humphreys E, Partin A and Walsh P. Impact of salvage androgen deprivation therapy on overall survival in men with biochemical recurrence after radical prostatectomy. AUA Annual Meeting, 2009
177. Bañez L, Sun L, Trock B, Han M, Partin A, Aronson W, Terris M, Presti Jr. J, Kane C, Amling C, Moul J and **Freedland SJ**. Body mass index and prostate-specific antigen as a predictor of adverse pathology and biochemical recurrence following radical prostatectomy. AUA Annual Meeting, 2009
178. Hamilton R, Bañez L, Aronson W, Terris M, Kane C, Presti Jr. J, Amling C and **Freedland SJ**. Statin medication use and the risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH Database. AUA Annual Meeting, 2009
179. Klink J, Jayachandran J, Bañez L, Gerber L, Lark A, Vollmer R and **Freedland SJ**. Inflammation is associated with more aggressive prostate cancer. AUA Annual Meeting, 2009
180. Moreira D, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and **Freedland SJ**. Natural history of salvage radiotherapy for recurrent prostate cancer: Results from the SEARCH Database. AUA Annual Meeting, 2009
181. Presti Jr. J, Terris M, Kane C, Amling C and **Freedland SJ**. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? AUA Annual Meeting, 2009

182. Donovan M, Khan F, Fernandez G, Mesa-Tejada R, Sapir M, Bayer-Zubek V, Fogarsi S, Vengrenyuk Y, Teverovskiy M, Karnes J, Gaffey T, Busch C, **Freedland SJ**, Albertsen P, Costa J, Cordon-Cardo C. Prediction of disease progression including durable response to hormonal therapy at diagnosis using the prostate needle biopsy and pretreatment clinical variables. AUA Annual Meeting, 2009

183. Bañez L, Presti Jr. J, Terris M, Aronson W, Kane C, Amling C and **Freedland SJ**. Do H2 blockers lower serum PSA results? Data from the SEARCH Database. AUA Annual Meeting, 2009

184. Bañez L, De Nunzio C, Trucchi A, **Freedland SJ** and Tubaro A. Is PSA a poor predictor of prostate cancer in obese men? Results from a European Biopsy Cohort. AUA Annual Meeting, 2009

185. Bañez L, Iraggi J, Pearson S, Gerber L, Taylor L and **Freedland SJ**. Alcohol intake and the risk for prostate cancer in a multi-ethnic population of U.S. veterans: Is race an important factor? ASCO GU Cancers, 2009

186. Bañez L, Terris M, Aronson W, Presti Jr. J, Kane C, Amling C and **Freedland SJ**. Race and time from diagnosis to radical prostatectomy: Does equal-access mean equal timely access to the operating room? Results from the SEARCH Database. ASCO GU Cancers, 2009

187. Bañez L, Jayachandran J, Klink J, Lark A, Gerber L, Vollmer R and **Freedland SJ**. The association of obesity and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. ASCO GU Cancers, 2009

188. Teeter A, Presti Jr. J, Aronson W, Terris M, Kane C, Amling C and **Freedland SJ**. Does early PSADT (ePSADT) after radical prostatectomy, calculated using PSA values starting with the first detectable PSA values, correlate with standard PSADT? A report from the SEARCH Database Group. ASCO GU Cancers, 2009

189. Jayachandran J, Schroeck F, Sun L, Gerber L, Moreira D, Moul J and **Freedland SJ**. The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: Validation in the Duke Prostate Center (DPC) database. ASCO GU Cancers, 2009

190. Heiden E, Weiss G, Bañez L, **Freedland SJ**, Sun L, Hartmann A, van Leenders G, Bangma C, Ittmann M and Wheeler T. PITX2 methylation and biochemical recurrence in post-radical prostatectomy prostate cancer patients. ASCO GU Cancers, 2009

191. Teeter A, Presti Jr. J, Aronson W, Terris M, Kane C, Amling C and **Freedland SJ**. Does PSADT after radical prostatectomy predict overall survival? A report from the SEARCH Database Group. ASCO GU Cancers, 2009

192. Moreira D, Bañez L, Amling C, Presti Jr. J, Terris M, Aronson W, Kane C and **Freedland SJ**. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: Results from the SEARCH Database. ASCO GU Cancers, 2009

193. Moreira D, Presti Jr. J, Aronson A, Terris M, Kane C, Amling C, Sun L, Moul J and **Freedland SJ**. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: Results from the SEARCH and DPC Databases. Society of Urological Oncology, 2009
194. Teeter A, Sun L, Moul J and **Freedland SJ**. External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: Results from the Duke Prostate Center Database. Society of Urological Oncology, 2009
195. Schroeck F, Kattan M, Moul J, Aronson W, Presti Jr. J, Terris M, Kane C, Amling C, Sun L and **Freedland SJ**. Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy (RP). Society of Urological Oncology, 2009
196. Bañez L, Iraggi J, Pearson S, Gerber L, Taylor L and **Freedland SJ**. Alcohol intake and the risk for prostate cancer in a multi-ethnic population of United States Veterans: Is race an important factor? Society of Urology Oncology, 2009
197. Thomas J, Masko E, Antonelli J, Poulton S, Phillips T, Coburn T and **Freedland SJ**. Differential effects of caloric and carbohydrate restriction upon prostate cancer tumor growth in a mouse model. Society of Urological Oncology, 2009
198. Masko E, Thomas J, Antonelli J, Lloyd H, Phillips T, Poulton S and **Freedland SJ**. Low-carbohydrate diets and prostate cancer growth: How low is “low enough”? Society of Urological Oncology, 2009
199. Whitley B, Masko E, Newgard C, Mavropoulos J, Poulton S, Phillips T, Pizzo S and **Freedland SJ**. Tissue amino acid levels are significantly decreased in mice fed a no-carbohydrate ketogenic diet compared to western diet. Society of Urological Oncology, 2009
200. Kim H, Moreira D, Jayachandran J, Gerber L, Bañez, Vollmer R, Lark A, Donovan M, Powell D, Khan F and **Freedland SJ**. Prostate biopsies from African-American men express higher levels of aggressive disease biomarkers than prostate biopsies from Caucasian men. Society of Urological Oncology, 2009
201. **Freedland SJ**, Marberger M, Andriole G, Pettaway C, Wilson T, Somerville M, Fowler I and Rittmaster R. Influence of baseline serum testosterone and DHT levels on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. ASCO GU Cancers, 2010
202. Moreira D, Antonelli J, Presti Jr. J, Aronson W, Terris M, Kane C and **Freedland SJ**. Association of cigarette smoking with time to biochemical recurrence after radical prostatectomy: Results from the SEARCH database. ASCO GU Cancers, 2010
203. Teeter A, Sun L, Moul J and **Freedland SJ**. External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: Results from the Duke Prostate Center database. ASCO GU Cancers, 2010

204. McDermed J, Klem R, Adams T, Diamandis E, **Freedland SJ**. Post-prostatectomy PSA determined with a nucleic acid detection immune-PCR assay (NADiA) as a prognostic indicator for risk of prostate cancer recurrence. ASCO GU Cancers, 2010
205. Teeter A, Presti J, Aronson W, Terris M, Amling C, Kane C and **Freedland SJ**. Does early PSA doubling time after radical prostatectomy correlate with overall survival? A report from the SEARCH database group. ASCO GU Cancers, 2010
206. Masko E, Thomas J, Antonelli J, Lloyd J, Phillips T, Poulton S, Pizzo S and **Freedland SJ**. Low-carbohydrate diets and prostate cancer growth: How low is “low enough”? AACR Annual Meeting, 2010
207. Whitley B, Masko E, Thomas J, Kim H, Poulton S, Phillips T and **Freedland SJ**. TRAMP- injected mice fed a no-carbohydrate ketogenic diet demonstrate prolonged survival and decreased tumor volumes compared to mice fed western or low-fat diets. AACR Annual Meeting, 2010
208. Williams C, Whitley B, Hoyo C, Grant D, Iraggi J, Newman K, Gerber L, Taylor L and **Freedland SJ**. Carbohydrate intake, glycemic load and glycemic index and prostate cancer risk. AACR Annual Meeting, 2010
209. Thomas J, Masko E, Antonelli J, Poulton S, Phillips T, Coburn T and **Freedland SJ**. Differential effects of caloric and carbohydrate restriction upon prostate cancer tumor growth in a mouse model. AACR Annual Meeting, 2010
210. Joshu C, Mondul A, Han M, Humphreys E, **Freedland SJ**, Walsh P and Platz E. Weight gain is associated with an increased risk of prostate cancer recurrence in the PSA era. AACR Annual Meeting, 2010
211. Teeter A, Aronson W, Presti Jr. J, Terris M Amling C, Kane C and **Freedland SJ**. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more distant prostate cancer outcomes than BCR?- A report from the SEARCH Database group. AUA Annual Meeting, 2010
212. Kim H, Moreira D, Jayachandran J, Gerber L, Bañez L, Vollmer R, Lark A, Donovan M, Powell D, Khan F and **Freedland SJ**. Prostate biopsies from African-American men express higher levels of aggressive disease biomarkers than prostate biopsies from Caucasian men? AUA Annual Meeting, 2010
213. Whitley B, Masko E, Newgard C, Mavropoulos H, Poulton S, Phillips T, Pizzo S and **Freedland SJ**. Tissue amino acid levels are significantly decreased in mice fed a no-carbohydrate ketogenic diet compared to western diet. AUA Annual Meeting, 2010
214. Teeter A, Sun L, Moul J and **Freedland SJ**. External validation of the SEARCH model for predicting aggressive recurrence after prostatectomy: Results from the Duke Prostate Center Database. AUA Annual Meeting, 2010

215. Moreira D, Gerber L, Thomas J, McKeever M, Bañez L and **Freedland SJ**. PSA doubling time (PSADT) predicts cancer for men undergoing repeat biopsy. AUA Annual Meeting, 2010
216. Thomas J, Masko E, Antonelli J, Poulton S, Phillips T, Coburn T and **Freedland SJ**. Differential effects of caloric and carbohydrate restriction upon prostate cancer. AUA Annual Meeting, 2010
217. Masko E, Bañez L, Valilis N, Phillips T, Poulton S, Solomon K, Pizzo S and **Freedland SJ**. The use of simvastatin and ezetimibe as novel therapeutics for prostate cancer in a xenograft model. AUA Annual Meeting, 2010
218. Masko E, Bañez L, Pizzo S and **Freedland SJ**. Simvastatin inhibits the growth of androgen-sensitive and androgen-independent cells in vitro. AUA Annual Meeting, 2010
219. Moreria D, Anderson T, Gerber L, Thomas J, McKeever M, Bañez L, Jayachandran J and **Freedland SJ**. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. AUA Annual Meeting, 2010
220. McNarmara E, Thomas J and **Freedland SJ**. Exercise correlates to higher sexual function scores in a cohort of healthy men. AUA Annual Meeting, 2010
221. Moreira D, Antonelli J, Presti Jr. J, Aronson W, Terris M, Kane C, Amling C and **Freedland SJ**. Association of cigarette smoking with time to biochemical recurrence after radical prostatectomy: Results from the SEARCH Database. AUA Annual Meeting, 2010
222. **Freedland SJ**, Terris M, Presti Jr. J, Kane C, Amling C and Aronson W. Race and long-term outcomes after radical prostatectomy: Results from the SEARCH Database. AUA Annual Meeting, 2010
223. Bañez L, Goldberg K, Hamilton R and **Freedland SJ** Weight gain is associated with lower PSA concentrations in men without hemodilution. AUA Annual Meeting, 2010
224. Masko E, Thomas J, Antonelli J, Lloyd J, Phillips T, Poulton S, Pizzo S and **Freedland SJ**. Low-carbohydrate diets and prostate cancer growth: How low is “Low enough”? AUA Annual Meeting, 2010
225. Moreira D, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and **Freedland SJ**. Does being on ADT alter the ability of PSA and PSADT to predict a positive bone scan? Results from the SEARCH Database. AUA Annual Meeting, 2010
226. Andriole G, **Freedland SJ**, Tindall D, Tammela T, Teloken C, Somerville M, Wilson T and Rittmaster R. Utility of combining final PSA and PSA Dynamics (Change from month 6 to final PSA) for prostate cancer and high grade cancer diagnosis in the reduction by dutasteride of prostate cancer events (REDUCE) study. AUA Annual Meeting, 2010

227. McNamara E, Mao L, Poulton S, Rockman H, Bivalacqua T and **Freedland SJ** and Donatucci C. Effect of exercise on erectile function after bilateral nerve crush injury in a rat model. AUA Annual Meeting, 2010
228. Antonelli J, Jones L, Thomas J, Masko E, Lloyd J, Poulton S, Phillips T, Tewari A, Febbo P, Pollak M, Dewhirst M and **Freedland SJ**. Effect of voluntary wheel running on growth of prostate cancer in immunocompromised and immunocompetent mouse models. AUA Annual Meeting, 2010
229. Bañez L, Gerber L, Aronson W, Presti Jr. J, Terris M, Amling C, Kane C and **Freedland SJ**. Does initiating statin therapy after radical prostatectomy reduce the risk for biochemical recurrence? Results from the SEARCH Database. AUA Annual Meeting, 2010
230. Teeter A, Aronson W, Presti Jr. J, Terris M, Amling C, Kane C and **Freedland SJ**. Does PSA doubling time after radical prostatectomy correlate with overall survival? A report from the SEARCH Database group. AUA Annual Meeting, 2010
231. Lloyd J, Antonelli J, Phillips T, Masko E, Thomas J, Poulton S, Pollack M and **Freedland SJ**. Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model. AUA Annual Meeting, 2010
232. Lloyd J, Masko E, Antonelli J, Thomas J, Aronson W and **Freedland SJ**. Does type of dietary fat matter? Prostate cancer xenograft progression in a scid mouse model with varying dietary fat sources. AUA Annual Meeting, 2010
233. Chu D, Moreira D, Gerber L, McKeever M, **Freedland SJ** and Bañez L. The impact of abnormal digital rectal examination on prostate cancer detection in obese men. Society of Urological Oncology, 2010
234. Stewart S, Xie D, **Freedland SJ**, Robertson C, Polascik T, Walther P, Koontz B, Vujaskovic Z, Lee R, Febbo P, George D, Armstrong A, Moul J and Bañez L. Does the multidisciplinary approach improve oncologic outcomes in men undergoing surgical treatment for prostate cancer? Society of Urological Oncology, 2010
235. Stewart S, Bañez L, Xie D, **Freedland SJ**, Robertson C, Polascik T, Walther P, Koontz B, Vujaskovic Z, Lee R, Armstrong A, Febbo P, George D and Moul J. Utilization trends of a multidisciplinary prostate cancer clinic: Initial 5-year experience from the Duke Prostate Center. Society of Urological Oncology, 2010
236. Keto C, Bañez L, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and **Freedland SJ**. Prostate cancer specific and overall survival in men treated with early androgen deprivation therapy for PSA-only recurrence after radical prostatectomy: Results from the SEARCH Database. Society of Urological Oncology, 2010
237. Kopp R, Parsons K, Partin A, Humphreys E, **Freedland SJ** and Han M. Obesity and prostate enlargement in men with localized prostate cancer. Society of Urological Oncology, 2010

238. Thomas J, Presti Jr. J, Aronson W, Terris, Kane C, Amling C, **Freedland SJ** and Moreira D. Short time to PSA nadir after radical prostatectomy is associated with increased risk of biochemical recurrence: Results from the SEARCH Database. Society of Urological Oncology, 2010
239. Moreira D, Bañez L, Aronson W, Terris M, Amling C, Kane C, Presti Jr. J and **Freedland SJ**. Low serum folate is a risk factor for biochemical recurrence after radical prostatectomy: Results from the SEARCH Database. Society of Urological Oncology, 2010
240. Stroup S, **Freedland SJ**, Millard F, Terris M, Aronson W, Presti Jr. J, Amling C and Kane C. Presence of Gleason pattern 5 on biopsy: Subclassification of high risk patients from the SEARCH Database. Society of Urological Oncology, 2010
241. Ho T, Aronson W, Terris M, Presti Jr. J, Kane C, Amling C and **Freedland SJ**. Obese men are more likely to have higher PSA nadir values after radical prostatectomy (RP), though this does not explain the higher biochemical recurrence (BCR) rates: Results from the SEARCH database. ASCO GU Cancers, 2011
242. Wu C, Moreira D, Gerber L, Rittmaster S, Andriole G and **Freedland SJ**. Diabetes and cancer risk in the REDUCE trial. ASCO GU Cancers, 2011
243. Chu D, Moreira D, McKeever M, **Freedland SJ** and Bañez L. The impact of abnormal digital rectal examination on prostate cancer detection in obese men. Southeastern Section of the AUA, 2011
244. Klink J, Moreira D, Gerber L, Thomas J, McKeever M, Bañez L and **Freedland SJ**. In an equal access hospital, black men are less likely to get radical prostatectomy. Southeastern Section of the AUA, 2011
245. Bañez L, De Nunzio C, Trucchi A, Cantiani A, Albisinni S, **Freedland SJ** and Tubaro A. Evaluation of PSA accuracy for the detection of prostate cancer in obese men: Results from a European biopsy cohort. European Association of Urology Annual Meeting, 2011
246. De Nunzio C, **Freedland SJ**, Miano R, Trucchi A, Cantiani A, Esperto F, Brassetti A and Tubaro A. Metabolic syndrome and prostate cancer: A Possible link to prostate cancer aggressiveness. European Association of Urology Annual Meeting, 2011
247. Albisinni S, De Nunzio C, Tubaro A, Bañez L and **Freedland SJ**. The impact of androgen levels on the risk of high grade prostate cancer: Evaluating the free to total testosterone ratio. European Association of Urology Annual Meeting, 2011
248. Emberton M, Andriole G, **Freedland SJ**, Marberger M, Wilson T and Rittmaster RS. Undetected high-grade prostate cancers in the Reduction by Dutasteride of clinical progression Events (REDUCE) study using PSA monitoring guidelines. European Association of Urology Annual Meeting, 2011

249. Wu C, Masko E, Poulton S, Ho T, Gaines A and **Freedland SJ**. Effect of pomegranate and diet on prostate cancer tumor growth and survival. American Association for Cancer Research, 2011
250. Chu D, Masko E, Poulton S, Pizzo S and **Freedland SJ**. Cholesterol and ezetimibe: Effects on tumor growth and survival outcomes: An interim analysis. American Association for Cancer Research, 2011
251. Albisinni S, De Nunzio C, Tubaro A, Bañez L and **Freedland SJ**. The impact of androgen levels on the risk of high grade prostate cancer: Evaluating percent free testosterone. AUA Annual Meeting, 2011
252. Gerber L, Bañez L, **Freedland SJ**, Xie D, Qi J, Polascik T, Robertson C and Moul J. Diabetes mellitus and the risk of high-grade prostate cancer: results from the Duke Prostate Center. AUA National Meeting, 2011
253. Ho T, Aronson W, Terris M, Presti J, Kane C, Amling C and **Freedland SJ**. Obese men are more likely to have higher PSA nadir values after radical prostatectomy (RP), though this does not explain the higher biochemical recurrence (BCR) rates: Results from the SEARCH database. AUA National Meeting, 2011
254. Keto C, Kane C, Amling C, Presti J, Terris M, Aronson W and **Freedland SJ**. PSA nadir during androgen deprivation therapy predicts adverse prostate cancer specific outcomes: Results from the SEARCH database. AUA National Meeting, 2011
255. Keto C, Kane C, Amling C, Presti J, Terris M, Aronson W and **Freedland SJ**. Obesity is associated with castrate resistant disease and metastasis in men treated with androgen deprivation therapy (ADT) for PSA-only recurrence after radical prostatectomy (RP): results from the SEARCH database. AUA National Meeting, 2011
256. Caso J, Masko E, Thomas J, Poulton S, Dewhirst M, Pizzo S and **Freedland SJ**. The effects of Carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. AUA National Meeting, 2011
257. Kopp R, Stroup S, Gerber L, **Freedland SJ**, Terris M, Aronson W, Presti J Jr., Amling C, and Kane C. Do repeated prostate biopsies worsen the outcome among men with prostate cancer who have a radical prostatectomy? Results from the SEARCH database. AUA National Meeting, 2011
258. Kopp R, Parsons JK, Partin A, Humphreys E, **Freedland SJ**, and Han M. Obesity and prostate enlargement in men with localized prostate cancer. AUA National Meeting, 2011
259. Chu D, deNunzio C, Gerber L, Thomas J, Albisinni S, McKeever M, Moreira D, Senocak C, Moul J, **Freedland SJ** and Bañez L. Should a digital rectal examination be optional for early detection of prostate cancer in obese men? AUA National Meeting, 2011
260. Masko E, Moreira D, Bañez L, Hoyo C, Grant D, Calloway E, Shuler K, Newman K, Gaines A, Taylor L, Robertson C and **Freedland SJ**. Genetic variation in obesity-related genes

ADBR2, ADBR2, ADBR3, GHRL, HSD11B1 and SHC1 and risk of prostate cancer: a VA case-control study. AUA National Meeting, 2011.

261. Wu C, Masko E, Poulton S, Ho T, Gaines A and **Freedland SJ**. Effect of pomegranate and diet on prostate cancer tumor growth and survival. AUA National Meeting, 2011

262. Bañez L, Gerber L, Aronson W, Terris M, Presti J, Kane C, Amling C and **Freedland SJ**. Risk for recurrent prostate cancer increases with cholesterol on a continuum in men with abnormal cholesterol levels- an update from the SEARCH Database. AUA National Meeting 2011

263. Bañez L, Gerber L, Moreira D, McKeever M, Rittmaster R, Andriole G and **Freedland SJ**. Does hemodilution or decreased circulating androgens explain lower PSA concentrations among obese men? Results from the REDUCE Trial. AUA National Meeting, 2011

264. Bañez L, Hoyo C, Masko E, Calloway E, Shuler K, Newman K, Gaines A, **Freedland SJ** and Robertson C. Combination of ADH gene polymorphism and alcohol consumption constitutes a novel prostate cancer risk factor in African-American Men. AUA National Meeting, 2011

265. Masko E, Moreira D, Bañez L, Hoyo C, Grant D, Calloway E, Shuler K, Newman K, Gaines A, Taylor L, Robertson C and **Freedland SJ**. Genetic variation in obesity-related genes ADBR2, ADBR2, ADBR3, GHRL, HSD11B1 and SHC1 and risk of prostate cancer: A VA case-control study. American Association for Cancer Research, 2011.

266. Moreira D, Presti J, Aronson W, Terris M, Kane C, Amling C and **Freedland SJ**. Predictors of prostate cancer-specific mortality in patients with residual disease after radical prostatectomy: Results from the SEARCH database. American Urological Association, 2011

267. Moreira D, Presti J, Aronson W, Terris M, Kane C, Amling C and **Freedland SJ**. Extracapsular extension predicts who achieve undetectable PSA after radical prostatectomy: Results from the SEARCH database. American Urological Association, 2011.

268. **Freedland SJ**, Gerber L, Bañez L, Moreira D, Andriole G and Rittmaster R. Statin use of the risk of prostate cancer and high-grade prostate cancer: Results from the REDUCE study. AUA National Meeting, 2011

269. **Freedland SJ**, Gerber L, Bañez L, McKeever M, Moreira D, Andriole G and Rittmaster R. Do metabolic comorbidities influence the ability of dutasteride to lower prostate cancer risk? Results from the REDUCE study. AUA National Meeting, 2011

270. **Freedland SJ**, Gerber L, Bañez L, Moreira D, Andriole G and Rittmaster R. Obesity increases the risk of high-grade prostate cancer: Results from the REDUCE study. AUA National Meeting, 2011

271. Oh DS, Song H, Gerber L, **Freedland SJ**, Patel PR, Lewis SL, Yoo DS, Oleson JR, and Salama JK. Statin use and prostate cancer recurrence in men treated with brachytherapy, ASTRO, 2011
272. Masko EM, Solomon KR, Gaines AR, Betof A, Abern A, Valilis NA, Pizzo SV, **Freedland SJ**. The use of cholesterol-lowering Ezetimibe for prostate cancer prevention in the Hi-Myc and PTEN transgenic mouse models. AACR Metabolism and Cancer Conference, 2011
273. Punnen S, **Freedland SJ**, Presti J, Amling C, Terris M, Aronson W, Kane C, Carroll P, and Cooperberg M. Multi-institutional validation of UCSF cancer of the prostate risk assessment-postsurgical score for prediction of recurrence post radical prostatectomy. Society of Urologic Oncology, 2011
274. Keto C, Aronson W, Terris M, Presti J, Kane C, Amling C, and **Freedland SJ**. PSA NADIR during androgen deprivation therapy predicts adverse prostate cancer specific outcome: results from the SEARCH database. Society of Urologic Oncology, 2011
275. Stewart SB, Madden J, Gerber L, Polascik T, Robertson C, Walther P, **Freedland SJ**, Moul J, and Bañez L. Does the extent of positive surgical margins influence biochemical recurrence following radical prostatectomy? – Results from the Duke Prostate Center. Society of Urologic Oncology, 2011
276. Thomas JA II, Gerber L, Moreira D, Hamilton R, Bañez L, Castro-Santamaria R, Andriole G, Isaacs W, Xu J, and **Freedland SJ**. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study. Society of Urologic Oncology, 2011
277. Singh A, Bañez L, Gerber L, **Freedland SJ**, Robertson C, Ferrandino M, Polascik T, and Moul J. Perineural versus lymphovascular invasion: which is a better marker for unfavorable biochemical outcomes following prostatectomy? – Results from the Duke Prostate Center database. Society of Urologic Oncology, 2011
278. Singh A, **Freedland SJ**, Gerber L, Aronson W, Terris M, Presti J, Amling C, Kane C, and Bañez, L. Is clinical stage T2C prostate cancer intermediate or high-risk disease? – Results from the SEARCH database. Society of Urologic Oncology, 2011
279. Keto C, Kane C, Terris M, Amling C, Aronson W, Presti J, and **Freedland SJ**. A nomogram predicting ADT failure for men starting androgen deprivation therapy before metastatic disease: results from the SEARCH database. Society of Urologic Oncology, 2011
280. Gaines A, Keto C, Gerber L, and **Freedland SJ**. The association between race and prostate cancer risk on initial biopsy in a contemporary, multiethnic cohort. Society of Urologic Oncology, 2011
281. Singh A, Antonelli J, Jones L, Gerber L, Calloway E, Shuler K, Hoyo C, Grant D, **Freedland SJ**, and Bañez L. Physical activity and prostate cancer risk reduction: does race matter? Society of Urologic Oncology, 2011

282. Singh A, Gerber L, **Freedland SJ**, Aronson W, Terris M, Presti J, Amling C, and Bañez L. Is clinical stage T2c prostate cancer intermediate – or high-risk disease? Results from the SEARCH database. GU ASCO Annual Meeting, 2012
283. Basset M, Abern M, Bañez LL, Ferrandino M, Robertson CN, Inman BA, Polascik T, **Freedland SJ**, Walther PJ, and Moul J. African American race to predict earlier failure of active surveillance: Results from the Duke Prostate Center. GU ASCO Annual Meeting, 2012
284. Singh A, Bañez L, Gerber L, **Freedland SJ**, Robertson C, Ferrandino M, Polascik T, Walther P, and Moul J. Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database. GU ASCO Annual Meeting, 2012
285. Bañez L, Hoyo C, Gerber L, Moreira D, McKeever M, Andriole G, and **Freedland SJ**. Heavy ethanol intake and elevated prostate cancer risk among men with previous negative biopsies in the REDUCE trial. GU ASCO Annual Meeting, 2012
286. Singh A, Antonelli J, Jones L, Gerber L, Calloway E, Shuler K, Hoyo C, Grant D, **Freedland SJ**, and Bañez L. Physical activity and prostate cancer risk reduction: Does race matter? GU ASCO Annual Meeting, 2012
287. Muller R, Presti J, Aronson W, Terris M, Kane C, Amling C, and **Freedland SJ**. Does salvage radiation therapy (SRT) change the biology of recurrent prostate cancer (PCa) based on PSA doubling times (PSADT)? Results from the SEARCH database. GU ASCO Annual Meeting, 2012
288. Vidal A, Grant D, Williams C, Allott E, Masko E, **Freedland SJ**, and Hoyo C. Prostate cancer and B-vitamins. American Association for Cancer Research Annual Meeting, 2012
289. Allott E, Tang X, Masko E, Gaines A, Abern M, Chi J, and **Freedland SJ**. Methionine restriction limits prostate tumor cell proliferation. American Association for Cancer Research Annual Meeting, 2012
290. Masko E, Solomon K, Valilis N, Gaines A, Muehlbauer M, Newgard C, Dewhirst M, Pizzo S, and **Freedland SJ**. The effects of cholesterol treatment drugs alone and in combination on prostate tumor xenograft growth. American Association for Cancer Research Annual Meeting, 2012
291. Abern M, Masko E, Wu C, Gaines A, Pizzo S, and **Freedland SJ**. The effect of pomegranate extract dose on prostate cancer growth in a carbohydrate restricted mouse xenograft model. American Association for Cancer Research Annual Meeting, 2012
292. Guerrios L, Perez C, Irizarry-Ramirez M, and **Freedland SJ**. Diabetes mellitus as a risk factor for prostate cancer progression after radical prostatectomy in an Hispanic population. American Association for Cancer Research Annual Meeting, 2012

293. Stewart S, Madden J, Gerber L, Polascik T, Robertson C, Walther P, **Freedland SJ**, Moul J, and Bañez L. Does the extent of positive surgical margins influence biochemical recurrence following radical prostatectomy? Results from the Duke Prostate Center. Southeastern Section of AUA Annual Meeting, 2012
294. Singh A, Bañez L, Gerber L, **Freedland SJ**, Robertson C, Ferrandino M, Polascik T, Walther P, and Moul J. Perineural versus lymphovascular invasion: which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database. Southeastern Section of AUA Annual Meeting, 2012
295. **Freedland SJ**, Thomas J, Keto C, Aronson W, Presti J, Kane C, Amling C, and Terris M. Obesity and risk of metastatic disease after radical prostatectomy: Results from SEARCH. Southeastern Section of AUA Annual Meeting, 2012
296. Thomas J, Gerber L, Moreira D, Hamilton R, Bañez LL, Castro R, Andriole G, Isaacs W, Xu J, **Freedland SJ**. Prostate cancer risk in men with prostate and breast cancer family history: Results from the REDUCE study. AUA Annual Meeting, 2012
297. Thomas J, Masko E, Gaines A, Whitley B, Chi J, Aronson W, and **Freedland SJ**. Differential effect of caloric and carbohydrate restriction on prostate tumor cancer growth and gene expression in a xenograft model. AUA Annual Meeting, 2012
298. Thomas J, Antonelli J, Bañez L, Gerber L, Hoyo C, Grant D, Demark-Wahnefried W, Platz E, Calloway E, Eyoh E, Shuler K, and **Freedland SJ**. Androgenetic alopecia at various ages and prostate cancer risk in an equal access multiethnic case control series of veterans. AUA Annual Meeting 2012
299. Thomas J, Gerber L, Moreira D, Bañez L, Andriole G, and **Freedland SJ**. Is the association between Dutasteride use and prostate cancer risk different in men with a family history of breast or prostate cancers? AUA Annual Meeting, 2012
300. Masko E, Solomon K, Valilis N, Gaines A, Muehlbauer M, Newgard C, Dewhirst M, Pizzo S, and **Freedland SJ**. The effects of cholesterol treatment drugs alone and in combination on prostate tumor xenograft growth. AUA Annual Meeting, 2012
301. Gaines A, Keto C, Gerber L, and **Freedland SJ**. The association between race and prostate cancer risk on initial biopsy in a contemporary, multiethnic cohort. AUA Annual Meeting, 2012
302. Chu DI, Moreira DM, Gerber L, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and **Freedland SJ**. The effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access healthcare setting: results from the SEARCH database. AUA Annual Meeting, 2012
303. Punnen S, **Freedland SJ**, Presti J Jr., Kane C, Amling C, Terris M, Aaronson W, Carroll P, and Cooperberg M. Multi-institutional validation of the CAPRA-S score to predict outcomes after radical prostatectomy. AUA Annual Meeting, 2012

304. **Freedland SJ**, Carducci M, Kroegr N, Partin A, Rao J, Jin Y, Kerkoutian S, Wu H, Li Y, Creel P, Mundy K, Gurganus R, Fedor H, King S, Heber D, Zhang Y, and Pantuck A. A phase II randomized controlled trial of POMx vs. placebo prior to radical prostatectomy. AUA Annual Meeting, 2012
305. Singh A, **Freedland SJ**, Gerber L, Aronson W, Terris M, Presti J, Amling C, and Bañez L. Should clinical stage T2c prostate cancer be classified as intermediate- or high-risk? Results from the SEARCH database. AUA Annual Meeting, 2012
306. Gollapudi K, Galet C, Grogan T, Zhang H, Huang J, Elashoff D, Gerber L, **Freedland SJ**, Rettig M, and Aronson W. Is infiltration of tumor-associated macrophages predictive of biochemical recurrence after radical prostatectomy? AUA Annual Meeting, 2012
307. Moreira D, Bañez L, Aronson W, Presti J Jr., Terris M, Kane C, Amling C, and **Freedland SJ**. Low serum folate is a risk factor for biochemical recurrence after radical prostatectomy: Results from the SEARCH Database. AUA Annual Meeting, 2012
308. Abern M, Aronson W, Terris M, Presti J, Kane C, Amling C, and **Freedland SJ**. Delayed radical prostatectomy in Gleason 7 prostate cancer decreases time to biochemical recurrence: results from the SEARCH database. AUA Annual Meeting, 2012
309. Abern M, Masko E, Wu C, Gaines A, Pizzo S, and **Freedland SJ**. The effect of pomegranate extract dose on prostate cancer growth in a carbohydrate restricted mouse xenograft model. AUA Annual Meeting, 2012
310. Muller R, Gerber L, Moreira D, Andriole G, Parsons JK, Fleshner N, and **Freedland SJ**. Statins slow prostate growth: results from the Reduction by Dutasteride of Cancer Events (REDUCE) Trial. AUA Annual Meeting, 2012
311. Muller R, Gerber L, Moreira D, Andriole G, Parsons JK, Fleshner N, and **Freedland SJ**. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. AUA Annual Meeting, 2012
312. Muller R, Presti J Jr., Aronson W, Terris M, Kane C, Amling C, and **Freedland SJ**. Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. AUA Annual Meeting, 2012
313. Muller R, Faria E, Carvalhal G, Reis R, Mauad E, Carvalho A, and **Freedland SJ**. Association between family history of prostate cancer and positive biopsies in a Brazilian screening program. AUA Annual Meeting, 2012
314. Senocak C, Bañez L, Thomas JA, Muller R, Gerber L, Robertson C, Polascik T, **Freedland SJ**, Walther P, and Moul J. Does long-term aspirin use lower serum PSA levels? results from the Duke prostate center. AUA Annual Meeting, 2012
315. Tsivian M, **Freedland SJ**, Bañez L, Gerber L, Presti J Jr., Aronson W, Terris M, Kane C, Amling C, Moul J, and Polascik T. Unilateral prostate cancer: Analysis of predictors in SEARCH and Duke prostate center databases. AUA Annual Meeting, 2012

316. Brawer M, Cooperberg M, **Freedland SJ**, Swanson G, Stone S, Reid J, Gutin A, Carroll P, and Cuzick J. Development and validation of a multivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. SESAUA Annual Meeting, 2012

317. Moreira D, Nickel JC, Gerber L, Muller R, Andriole G, Castro-Santamaria R and **Freedland SJ**. Baseline prostate inflammation is associated with decreased risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Society of Urologic Oncology, 2012

318. Moreira D, Nickel JC, Gerber L, Muller R, Andriole G, Castro-Santamaria R and **Freedland SJ**. Smoking is associated with acute prostatic inflammation in men with a negative prostate biopsy: results from the REDUCE study. Society of Urologic Oncology, 2012

319. Brawer M, Cooperberg M, **Freedland SJ**, Swanson G, Stone S, Reid J, Gutin A, Carroll P and Cuzick J. Development and validation of a multivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. Society of Urologic Oncology, 2012

320. **Freedland SJ**, Gerber L, Reid J, Welbourn W, Gutin A, Sangale Z, Salama J and Stone S. CCP score significantly predicts PSA failure after EBRT. Society of Urologic Oncology, 2012

321. Muller R, Aronson W, Terris M, Kane C, Amling C, Presti J, Jr. and **Freedland SJ**. Salvage radiation therapy after recurrent prostate cancer: how early do we need to be? Society of Urologic Oncology, 2012

322. Muller R, Faria E, Carvalhal G, Reis R, Mauad E, Carvalho A and **Freedland SJ**. Distance to biopsy site increases non-compliance to prostate biopsy in a large screening program in Brazil. Society of Urologic Oncology, 2012

323. **Freedland SJ**, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, and Stone S. Prognostic utility of CCP score in men with prostate cancer after external beam radiation therapy. GU ASCO, 2013

324. Brawer M, Cooperberg M, **Freedland SJ**, Swanson G, Stone S, Reid J, Gutin A, Carroll P and Cuzick J. Development and validation of a multivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. GU ASCO, 2013

325. Brawer M, Cuzick J, Cooperberg M, Swanson GP, **Freedland SJ**, Reid JE, Fisher G, Lanchbury JS, Gutin A, Stone S, Carroll P. Prolaris: A novel genetic test for prostate cancer prognosis. ASCO Annual Meeting, 2013

326. Cuzick J, Cooperberg M, Swanson GP, **Freedland SJ**, Reid JE, Fisher G, Lanchbury JS, Gutin A, Stone S, Carroll P, and Brawer M. Prolaris: A novel genetic test for prostate cancer prognosis. New England Section of the AUA Annual Meeting, 2013

327. McDonald AC, Vira M, **Freedland SJ**, Vidal AC, Gan W, Taioli W. Associations between systemic inflammatory markers and elevated serum prostate specific antigen in men with no evidence of prostatic disease. AACR Frontiers in Cancer Prevention Research, 2013

328. Moreira D, Nickel JC, Bostwick D, Gerber L, Muller R, Andriole G, Castro-Santamaria R, **Freedland SJ**. Baseline prostate atrophy is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study. Society of Urologic Oncology, 2014

329. Moreira D, Fleshner N, **Freedland SJ**. Baseline perineural invasion is associated with shorter time to progression in men with prostate cancer undergoing active surveillance: Results from the REDEEM study. Society of Urologic Oncology, 2014

330. McGinley K, Sun SX, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, **Freedland SJ**. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the SEARCH database. Society of Urologic Oncology, 2014

331. McGinley K, Sun SX, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, **Freedland SJ**. Can Gleason 7 prostate cancer ever be low-risk? Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Society of Urologic Oncology, 2014

332. Fischer S, Simon R, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, **Freedland SJ**. Pathological Gleason 8-10: Do all men do poorly? Results from the SEARCH database. Society of Urologic Oncology, 2014

333. Simon R, Howard L, **Freedland SJ**, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Vidal A. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? SESAUA Annual Meeting, 2014

334. Klaassen Z, Howard LE, Moreira DM, Andriole GL, Terris MK. Are lower PSA levels in obese men due to hemodilution or low androgens? Results from REDUCE. SESAUA Annual Meeting, 2014

335. Fischer S, Simon R, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, **Freedland SJ**, Vidal A. Pathological Gleason 8-10: Do all men do poorly? Results from the SEARCH database. SESAUA Annual Meeting, 2014

336. McGinley K, Sun X, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, **Freedland SJ**. Can Gleason 7 prostate cancer ever be low-risk? Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. SESAUA Annual Meeting, 2014

337. Klaassen Z, Howard L, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, **Freedland SJ**. Does larger tumor volume explain the higher PSA levels in black men with prostate cancer – results from the SEARCH Database. SESAUA Annual Meeting, 2014

338. McGinley K, Sun SX, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, **Freedland SJ**. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the SEARCH database. SESAUA Annual Meeting, 2014

339. Simon R, Howard L, Zapata D, Frank J, **Freedland SJ**, Vidal A. Exercise and better erectile function: how much exercise is needed and does race matter? SESAUA Annual Meeting, 2014